[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 522
1. Nassif AE, Tâmbara Filho R, Paula RX, Taguchi WS, Pozzobon HJ: [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment]. Rev Col Bras Cir; 2009 Aug;36(4):327-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiologic profile and prognostic factors in clinically localized prostate adenocarcinoma submitted to surgical treatment].
  • [Transliterated title] Perfil epidemiológico e fatores prognósticos no tratamento cirúrgico do adenocarcinoma de próstata clinicamente localizado.
  • OBJECTIVE: Radical prostatectomy remains the standard treatment for early prostate cancer.
  • METHODS: A total of 500 patients with prostate cancer underwent radical prostatectomy at Santa Rita hospital- Maringa-PR, between 2000 and 2006.
  • Clinical staging, preoperative prostate-specific antigen (PSA) and Gleason score were evaluated with pathological stage and margin status.
  • The patients' preoperative serum PSA was 7,8 + or - 4,5 ng/dl , with a higher proportion of Gleason Score < 6(72%) and The TNM stage pT2c (65%).
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076923.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


2. Armatys SA, Koch MO, Bihrle R, Gardner TA, Cheng L: Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma? BJU Int; 2005 Oct;96(6):777-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?
  • OBJECTIVE: To test the hypothesis that prostate cancer patients with clinical stage cT1c and cT2 have similar outcomes and clinicopathological features, and should be grouped together.
  • PATIENTS AND METHODS: From a series of men with prostate cancer who had a radical retropubic prostatectomy (RP), we assessed those with cT1c (223) and cT2 (65) adenocarcinoma.
  • RESULTS: Patients with cT2 tumours were more likely to have a higher Gleason score (P = 0.04) and final pathological stage (P = 0.05) than those with cT1c tumours.
  • There was no significant difference in age (P = 0.92), preoperative PSA level (P = 0.17), prostate weight (P = 0.34), tumour volume (P = 0.16), surgical margin status (P = 0.86), multifocality (P = 0.92), the presence of perineural invasion (P = 0.09), or high-grade prostatic intraepithelial neoplasia (P = 0.99) between patients with clinical stage cT1c and those with cT2 tumours.
  • There was no difference in PSA recurrence between patients with clinical stage T1c and those with cT2 tumours (P = 0.27).
  • CONCLUSIONS: Patients with clinical stage cT2 tumours have a higher Gleason score and advanced pathological stage than tumours detected because of a high serum PSA level (cT1c).
  • These results suggest that clinical stage cT1c tumours should be separated from clinical stage cT2 disease, but the PSA recurrence rate for both tumour stages is similar, indicating a need for further evaluation and refinement of the current clinical staging system.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16153198.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


3. Hung CF, Lee CH, Hung SW, Chiu KY, Cheng CL, Yang CR, Chen CJ, Li JR: Invasive adenocarcinoma of the prostate with urethral tumor. J Chin Med Assoc; 2010 Feb;73(2):101-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive adenocarcinoma of the prostate with urethral tumor.
  • Metastases of prostate cancer to the penis and urethra are rare and often represent advanced disease.
  • We describe a case of newly diagnosed prostatic adenocarcinoma with metastases to the corpus spongiosum, cavernosum, and the anterior urethra.
  • His prostate-specific antigen level was 5.02 ng/mL.
  • Digital rectal examination disclosed stony hard tumors at both lobes of the prostate.
  • Transrectal ultrasound-guided biopsy of the prostate revealed adenocarcinoma over both lobes; the Gleason score was 4 + 4 = 8.
  • Cystoscopy showed a penile urethral tumor and biopsy disclosed metastatic adenocarcinoma of the prostate; the Gleason score was 4 + 4 = 8.
  • Biochemical failure developed after 15 months and rapidly progressed to a hormone-refractory stage.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Prognosis. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20171591.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R: Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res; 2008 Aug 15;68(16):6822-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
  • Herein, using transgenic adenocarcinoma of the mouse prostate (TRAMP) model, we assessed the "stage-specific" efficacy of silibinin feeding against prostate cancer (PCa) initiation, progression, angiogenesis and metastasis, and associated molecular events involved in silibinin effects during these stages.
  • Male TRAMP mice starting at ages 4, 12, 20, and 30 weeks of age were fed with control or 1% silibinin-supplemented diet for 8 to 15 weeks in stage-specific manners.
  • During early stages of prostate tumor development, silibinin mediated its efficacy mostly via antiproliferative mechanisms.
  • Feeding of silibinin to animals burdened with higher stages of prostate tumor significantly decreased tumor grade via antiproliferative effect, and inhibition of angiogenesis as evidenced by decreased expressions of platelet endothelial cell adhesion molecule-1/CD-31, vascular endothelial growth factor, and associated receptor, vascular endothelial growth factor R2, hypoxia-inducible factor-1alpha, and inducible nitric oxide synthase.
  • Together, these findings are both novel and highly significant in establishing the dual efficacy of silibinin where it inhibits progression of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage metastasis.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15809-14 [9861052.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2104-15 [16208706.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Nov;5(6):603-12 [16305482.001]
  • [Cites] Annu Rev Med. 2006;57:49-63 [16409136.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):436-42 [16637061.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Aug;20(4):831-43 [16861117.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):751-78 [16954429.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1862-74 [17043660.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(6):1082-8 [17416542.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5976-82 [17575168.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):475-83 [17691907.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S9-S13 [17644117.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11083-91 [18006855.001]
  • [Cites] Food Chem Toxicol. 2008 Apr;46(4):1334-45 [17919802.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6777-82 [11559550.001]
  • [Cites] Cancer Invest. 2002;20(1):139-53 [11852996.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):933-9 [14504208.001]
  • [Cites] Endocr Rev. 2003 Oct;24(5):600-32 [14570746.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):272-80 [14663466.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Toxicol Pathol. 1996 Jul-Aug;24(4):502-4 [8864193.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4325-6 [16179603.001]
  • (PMID = 18701508.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112304-04; United States / NCI NIH HHS / CA / R01 CA112304; United States / NCI NIH HHS / CA / R01 CA112304-04; United States / NCI NIH HHS / CA / R01CA102514; United States / NCI NIH HHS / CA / R01 CA102514
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Silymarin; 0 / Vascular Endothelial Growth Factor A; 4RKY41TBTF / silybin; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ NIHMS55332; NLM/ PMC2587411
  •  go-up   go-down


5. Marcu M, Radu E, Sajin M: Neuroendocrine differentiation in prostate adenocarcinoma biopsies and its correlation to histological grading. Curr Health Sci J; 2010 Jan;36(1):37-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiation in prostate adenocarcinoma biopsies and its correlation to histological grading.
  • Prostate adenocarcinoma is frequently diagnosed on needle biopsies in early, organ-confined stages.
  • New prognostic factors would help identifying at this stage patients at risk for unfavorable evolution, that would benefit from alternate therapy.
  • This study aims to find correlations between the extent of neurocrine differentiation (NED), a feature commonly seen in prostate carcinoma, and known factors of disease evolution such as histological grade, malignant cell proliferation and serum PSA levels.
  • Immunohistochemistry for choromogranin A and neuron-specific enaolase (NSE) was used to calculate expression scores in order to asses the extent of NED in prostate biopsies.
  • Multinomial regression analysis showed that high Ki indices, serum PSA values and NSE scores are predictive for moderately and poorly differentiated prostatic adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24778825.001).
  • [ISSN] 2067-0656
  • [Journal-full-title] Current health sciences journal
  • [ISO-abbreviation] Curr Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3945267
  • [Keywords] NOTNLM ; Neuroendocrine differentiation / Prostate adenocarcinoma
  •  go-up   go-down


6. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A: Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol; 2008 Jan;172(1):236-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
  • The transgenic adenocarcinoma of mouse prostate (TRAMP) model is widely used in prostate cancer research because of rapid tumor onset and progression.
  • The strong genetic component of susceptibility to prostate cancer in humans prompted us to investigate the effect of mouse strain background (FVB and B6) on incidence, progression, and pathology of prostate cancer in this model.
  • Thus, neuroendocrine carcinomas are the principal malignancy in this model and may develop from bipotential progenitor cells at an early stage of prostate tumorigenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2000 Jun 1;43(4):263-71 [10861745.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1147-51 [10923074.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):831-2 [11395567.001]
  • [Cites] Semin Cancer Biol. 2001 Jun;11(3):245-60 [11407949.001]
  • [Cites] Reprod Fertil Dev. 2001;13(4):285-96 [11800167.001]
  • [Cites] Cell. 2002 Jan 25;108(2):145-52 [11832205.001]
  • [Cites] Trends Genet. 2002 May;18(5):S1-5 [12047956.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):727-35 [12163397.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):44462-74 [12228243.001]
  • [Cites] Curr Drug Targets. 2003 Apr;4(3):263-79 [12643476.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):181-9 [14522252.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4471-6 [15070742.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):225-54 [15163300.001]
  • [Cites] Toxicol Pathol. 2004 Jul-Aug;32(4):418-25 [15204965.001]
  • [Cites] Mol Cancer Res. 2004 Sep;2(9):504-13 [15383629.001]
  • [Cites] Prostate. 1986;8(3):209-20 [3703742.001]
  • [Cites] Biol Reprod. 1986 Jun;34(5):973-83 [3730489.001]
  • [Cites] Prog Clin Biol Res. 1987;239:251-72 [3309957.001]
  • [Cites] Prog Clin Biol Res. 1987;239:273-82 [3309958.001]
  • [Cites] Development. 1989 Jun;106(2):235-50 [2591313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Feb;18(2):188-96 [9476905.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):361-71 [10453280.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 2):S13-6; discussion S17 [15535436.001]
  • [Cites] J Urol. 2005 Feb;173(2):342-59 [15643172.001]
  • [Cites] J Urol. 2005 Feb;173(2):360-72 [15643173.001]
  • [Cites] Prostate. 2005 Mar 1;62(4):339-52 [15389796.001]
  • [Cites] Bull Cancer. 2005 Feb;92(2):129-41 [15749642.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] Vet Pathol. 2005 May;42(3):306-14 [15872376.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7180-5 [15899981.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6640-50 [16061644.001]
  • [Cites] Prostate. 2006 Jul 1;66(10):1013-28 [16001449.001]
  • [Cites] Prog Mol Subcell Biol. 2005;40:183-216 [17153485.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • (PMID = 18156212.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / 5P50CA089520-04; United States / NCI NIH HHS / CA / U01 CA084294; United States / PHS HHS / / U01 84244; United States / NCRR NIH HHS / RR / U42 RR14905; United States / NCRR NIH HHS / RR / U42 RR014905; United States / NCI NIH HHS / CA / P30 CA93373-01; United States / NCI NIH HHS / CA / U01 CA84294; United States / NCI NIH HHS / CA / P50 CA089520
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2189611
  •  go-up   go-down


7. Morán Pascual E, Dicapua Sacoto C, Trassierra Villa M, Pontones Moreno JL, Ruiz Cerdá JL, Jiménez Cruz JF: [Watchful waiting in incidental adenocarcinoma of the prostate]. Actas Urol Esp; 2010 Nov;34(10):854-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Watchful waiting in incidental adenocarcinoma of the prostate].
  • [Transliterated title] Actitud expectante en el adenocarcinoma incidental de próstata.
  • OBJECTIVE: To describe the outcome of patients diagnosed of incidental prostate adenocarcinoma managed by watchful waiting.
  • MATERIAL AND METHODS: We included patients with PSA< 4 ng/mL or higher with previous negative biopsy, who underwent surgery for BPH being diagnosed of incidental prostate adenocarcinoma.
  • Progression variables were: age, preoperative and postoperative PSA, stage, Gleason score, prostate volume, initial treatment, PSA evolution and salvage treatment if necessary.
  • RESULTS: 47 patients were diagnosed of incidental prostatic adenocarcinoma, finding an incidence of 4.25%.
  • Postoperative PSA and Gleason score showed up as prognostic variables of progression in T1a stage and postsurgery PSA did so in T1b patients.
  • CONCLUSION: Watchful waiting is a useful option in patients with incidental prostate adenocarcinoma and favourable prognostic criteria.
  • Postoperative PSA and Gleason score can predict progression in T1a stage and postoperative PSA in T1b stage.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Watchful Waiting

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159280.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. San Miguel Fraile P, Dos Santos JE, Pélaez Boismorand E, Ortiz Rey JA, Iglesias Rodríguez B, Cambronero Santos J, Fajardo Seijo JL, Rodríguez Costas JM, Fernández Regueiro M: [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma]. Actas Urol Esp; 2005 Jan;29(1):64-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma].
  • [Transliterated title] Estudio de la expresión de cerbB-2 en el adenocarcinoma de próstata.
  • OBJECTIVES: Our aim is to determine the expression of the cerbB-2 oncoprotein in prostate cancers using an immunohistochemistry staining and to compare these results with several clinical and histological prognostic factors.
  • METHODS: An immunohistochemical staining using the cerbB-2 monoclonal antibody (Dako) was performed in 32 radical prostatectomy specimens diagnosed of adenocarcinoma.
  • Such overexpression was correlated with higher Gleason grade (p=0.04) and higher stage of disease (p=0.038). CONCLUSIONS:.
  • 1) This study shows that 44% of all prostate cancer express the cerbB-2 oncoprotein with immunohistochemical technique.
  • 2) These findings suggest that is necessary to standardize the immunohistochemical staining procedure with cerbB-2 in prostate adenocarcinoma.
  • 3) The level of cerbB-2 expression was correlated with Gleason grade and clinical stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15786765.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Urbanskiĭ AI: [Correlation between size and localization of stage-pT adenocarcinoma of the prostate]. Vopr Onkol; 2006;52(6):649-53
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between size and localization of stage-pT adenocarcinoma of the prostate].
  • According to the data on resected material sampled from 58 cases of radical prostatectomy, a relationship between size of adenocarcinoma and prostate and localization of the main tumor node, on the one hand, and pathological stage (pT) of primary tumor was established.
  • Incidence of pT3 was dependent on tumor volume when adenocarcinoma was in the periphery of the prostate which involved the following relationships between pT, on the one hand, and tumor size and site, on the other: the closer tumor to the gland center, the lower the value of pT.
  • Risk of pT3 appeared to be associated with small size of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338242.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


10. Khouaja K, Ben Sorba N, Bouslama A, Youssef A, Taher Mosbah A: [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre]. Prog Urol; 2005 Apr;15(2):255-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
  • [Transliterated title] Une expérience de diagnostic individuel et précoce du cancer de la prostate dans le centre de la Tunisie.
  • INTRODUCTION: The introduction of prostate specific antigen (PSA) and progress in transrectal ultrasound and ultrasound-guided prostatic biopsies have allowed considerable progress in the diagnosis of prostate cancer.
  • However prostate cancer is still usually diagnosed at an advanced stage in Tunisia.
  • METHODS: We prospectively evaluated the prevalence of localized prostate cancer in the population of a Tunisian centre during a screening programme.
  • Prostatic biopsies were performed in 59 of these 92 patients with PSA between 4 and 20 ng/ml and revealed 18 cancers: 3 stage pN+ and 15 stage pN0, including 1 stage pT3 and 14 stage pT2 after radical prostatectomy.
  • 14 cancers detected in a population of 642 men (2.2%) were therefore stage pT2.
  • All underwent surgical prostatic disobstruction demonstrating adenocarcinoma.
  • CONCLUSION: Early individualized screening is possible in Tunisia and allows the detection of localized prostate cancer in 77% of patients with PSA less than 20 ng/ml.
  • The use of prostatic biopsies in the case of abnormal screening tests improves the management of prostate cancer in Tunisia.
  • [MeSH-minor] Aged. Early Diagnosis. Humans. Male. Middle Aged. Prospective Studies. Prostate-Specific Antigen / blood. Tunisia

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999603.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


11. Delaporte V, Muracciole X, Lechevallier E, Bastide C, Cowen D, Rossi D, Coulange C: [Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy]. Prog Urol; 2005 Apr;15(2):260-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy].
  • [Transliterated title] Cancer de la prostate à haut risque de rechute. Résultats d'une RT-HT de 12 mois.
  • OBJECTIVE: To evaluate the risk of progression after conformal radiotherapy combined with 12 months of adjuvant hormone therapy in a series of patients with prostate cancer considered to be at high risk of progression.
  • All patients presented at least one factor of the high-risk group of Amico's classification: TNM 92 stage T2c, T3 or T4, or Gleason score > or = 8 or baseline PSA > 20 ng/ml.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Androgen Antagonists / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999604.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


12. Rioja Zuazu J, Zudaire Berbera JJ, Rincón Mayans A, Rosell Costa D, Robles Garcia JE, Berian Polo JM: [Gleason score 8-10 prostatic adenocarcinoma: prognostic influence in the biochemical progression free survival]. Actas Urol Esp; 2008 Sep;32(8):792-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gleason score 8-10 prostatic adenocarcinoma: prognostic influence in the biochemical progression free survival].
  • [Transliterated title] Adenocarcinoma de próstata gleason clínico 8-10: influencia pronóstica en la supervivencia libre de progresión bioquímica.
  • OBJECTIVE: Hereby, we analyze the characteristics of the clinical Gleason 8-10 group of patients with in our series diagnosed of Prostate Cancer and treated by means of radical prostatectomy, and we try to ascertain which are the influence factors within this group upon progression and progression free survival.
  • MATERIAL AND METHODS: From the global series of 781 patients with T1-T2 prostate cancer treated by means of radical prostatectomy between 1990 and 2004, we study 108 with a Gleason score on the biopsy of 8-10.
  • In the multivariate study of the influence factors on the PFS includes Clinical Gleason Score 8-10 as an independent prognostic factor (OR: 2.6 IC 95%: 1.6-4.12) p = 0.003, together with the clinical stage (OR: 1.,81 IC 95%: 1.18-2.78) p < 0.006, the PSA (OR: 1.03 IC 95%: 1.025-1.046) p < 0.0001 and the side of tumor on the biopsy (OR: 1.5 IC 95%: 1.01-2.24) p = 0.045.
  • PSA (OR: 1.02 IC 95%: 1.003-1.04) and pathological stage (OR: 3.84 IC 95%: 1.77-8.27).
  • CONCLUSIONS: Clinical Gleason Score 8-10 is a negative independent prognostic factor on the progression free survival, but its prognosis is better if they present a PSA prior surgery lower than 11 ng/ml and the pathological stage is a pT2.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Biopsy. Disease-Free Survival. Humans. Male. Prognosis. Prostate-Specific Antigen / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013977.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


13. Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA: Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol; 2009 Dec;182(6):2689-94
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological behavior of single focus prostate adenocarcinoma.
  • PURPOSE: With the increasing use of focal therapy for prostate adenocarcinoma a pathological basis for its appropriate application must be established.
  • We determined the clinicopathological characteristics and natural history of single focus prostate cancer since this entity seems to be the ideal target for focal therapy.
  • MATERIALS AND METHODS: We queried the Center for Prostate Disease Research database for all patients who underwent radical prostatectomy at Walter Reed Army Medical Center from 1993 through 2008.
  • Patients with single focus prostate adenocarcinoma were compared with those who had multifocal disease.
  • Primary outcomes were surgical margin status, pathological stage and biochemical recurrence.
  • CONCLUSIONS: Single focus prostate cancer appears to have more aggressive behavior than multifocal disease.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836800.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • Most pts had PP advanced (22,7 % stage III; 68,2% stage IV) BCa.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Winkfield KM, Chen M, Dosoretz DE, Salenius SA, Katin MJ, Ross R, D'Amico AV: Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. J Clin Oncol; 2009 May 20;27(15_suppl):5068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.
  • : 5068 Purpose: We investigated whether race was associated with risk of death following brachytherapy-based treatment for localized prostate cancer.
  • METHODS: The study cohort was comprised of 4,880 men with clinical stage T1-3N0M0 prostate cancer and minimum follow-up of 2 years who underwent brachytherapy-based treatment at 20 centers within the 21st Century Oncology consortium.
  • A Cox regression multivariable analysis was used to evaluate the risk of death in African-American (AA) and Hispanic (H) men as compared to Caucasian men adjusting for age, pretreatment PSA, Gleason score, clinical T stage, year and type of treatment, and comorbidity level.
  • CONCLUSIONS: African-American and Hispanic race as compared to white race appear to confer a higher risk of mortality following brachytherapy-based treatment in men with localized or locally advanced prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964249.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP).
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jeet V, Ow K, Doherty E, Curley B, Russell PJ, Khatri A: Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. Prostate; 2008 Apr 1;68(5):548-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
  • BACKGROUND: The transgenic adenocarcinoma of the mouse prostate (TRAMP) model closely mimics PC-progression as it occurs in humans.
  • However, the timing of disease incidence and progression (especially late stage) makes it logistically difficult to conduct experiments synchronously and economically.
  • Epithelial origin (cytokeratin) and expression of late stage biomarkers (E-cadherin and KAI-1) were evaluated using immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Androgens / metabolism. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247402.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cd82 antigen, mouse; 0 / Receptors, Androgen
  •  go-up   go-down


19. Greenlee JE, Clawson SA, Hill KE, Dechet CB, Carlson NG: Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci; 2010 Apr 15;291(1-2):74-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate.
  • Paraneoplastic neurological syndromes are unusual in prostatic cancer, and paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate is rare.
  • Here we report a 68year old man who developed progressive ataxia in the setting of stage D2 adenocarcinoma of the prostate and whose MRI showed cerebellar atrophy.
  • Sera from neurologically normal patients with adenocarcinoma of the prostate did not contain this antibody, and the patient's serum did not react with normal prostate or with prostatic adenocarcinomas from other individuals.
  • Prostatic adenocarcinoma may occasionally be accompanied by development of anticerebellar antibodies.
  • Adenocarcinoma of the prostate should be considered as a possible underlying malignancy in older males with unexplained progressive cerebellar degeneration.
  • [MeSH-major] Adenocarcinoma / immunology. Autoantibodies / blood. Brain / immunology. Neurons / immunology. Paraneoplastic Cerebellar Degeneration / immunology. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 20089262.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies
  •  go-up   go-down


20. Uthoff D, Schmidt S, Matthies C, Tiemann M, Wagner W: [Coincidence of adenocarcinoma and MALT lymphoma of the prostate--first report]. Aktuelle Urol; 2009 Mar;40(2):113-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Coincidence of adenocarcinoma and MALT lymphoma of the prostate--first report].
  • [Transliterated title] Koinzidenz Adenokarzinom und MALT-Lymphom der Prostata--Eine Erstbeschreibung.
  • INTRODUCTION: First description of a prostate adenocarcinoma coinciding with the rare MALT lymphoma of the prostate.
  • CASE REPORT: 68-year-old patient with a pT2c, pN0, M0, Gleason 3 + 3 prostate carcinoma (retropubic radical prostatectomy with pelvic lymphadenectomy) and systemic indolent MALT lymphoma of the prostate (bone marrow biopsy).
  • CONCLUSION: MALT lymphomas of the prostate are rare, and so far a coincidence with a prostate carcinoma is unprecedented.
  • The prostate carcinoma is treated according to stage, while the MALT lymphoma is managed according to individual treatment strategies.
  • The pathogenesis of the MALT lymphoma of the prostate cannot yet be clarified definitively according to a literature review.
  • [MeSH-major] Adenocarcinoma / surgery. Lymphoma, B-Cell, Marginal Zone / surgery. Neoplasms, Multiple Primary / surgery. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow Neoplasms / pathology. Bone Marrow Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Prostate / pathology. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177323.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Samaratunga H, Delahunt B: Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol; 2008 Aug;30(4):237-46
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.
  • OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).
  • DAP is found in both the periurethral region and peripheral zone of the prostate and is considered high grade in the modified Gleason grading system.
  • Immunostaining for prostatic-specific antigen and prostate-specific acid phosphatase is present in these tumors, a high percentage of which overexpress alpha-methylacyl-coenzyme A racemase.
  • This usually represents an advanced stage of tumor progression and is not a precursor of invasive carcinoma.
  • CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.
  • DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


22. Veshapidze N, Alibegashvili M, Gabunia N, Ramishvili L, Kotrikadze N: Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate. Georgian Med News; 2009 Jan;(166):9-12
Hazardous Substances Data Bank. SODIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate.
  • The aim of our study was to investigate the alterations of the erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate before and six months after castration.
  • For experimental research were used the erythrocytes of 15 men with metastatic prostate cancer (Pca) (before and after 6 months from castration) and of the 15 practically healthy men (control group).
  • Clinical stage of the disease was established at A.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Membrane Permeability / physiology. Erythrocyte Membrane / metabolism. Prostatic Neoplasms / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202209.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 9NEZ333N27 / Sodium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium
  •  go-up   go-down


23. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, Filetti S, Bianchi G, Russo D: Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology; 2010 Apr;75(4):773-8
Hazardous Substances Data Bank. IODINE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the sodium/iodide symporter in human prostate adenocarcinoma.
  • OBJECTIVE: To analyze expression of the sodium/iodide symporter (NIS) in tissue specimen from a large series of patients with prostate adenocarcinoma.
  • Few data are available on the NIS expression in prostate tumor tissues.
  • The relationship between NIS expression and Gleason score, prostate-specific antigen levels and stage was also investigated.
  • RESULTS: NIS protein was expressed in 41 of 78 prostate cancer (52.4%) and was located predominantly intracellularly, whereas immunoreactivity was missing in nontumor hyperplastic prostatic tissue.
  • A statistically significant relationship was detected between presence of NIS expression and some markers of aggressiveness including stage > or =pT2a (P = .007) and Gleason score > or =8 (P = .014).
  • CONCLUSIONS: Our data demonstrate the presence of NIS transcript and protein in about half of prostate cancer tissues and its relationship with clinical markers of aggressiveness.
  • Thus, it may potentially serve as a biomarker for defining individuals with biologically active prostate cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Symporters / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19969326.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter; 9679TC07X4 / Iodine
  •  go-up   go-down


24. Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG: Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol; 2006;40(4):265-71
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
  • OBJECTIVE: To investigate adenocarcinoma of the prostate in a single population with an extended follow-up period.
  • MATERIAL AND METHODS: Using the Icelandic Cancer Registry, we identified all Icelandic men diagnosed with prostate cancer between 1983 and 1987.
  • Disease stage, initial treatment and follow-up information were obtained from hospital records and death certificates.
  • A critical evaluation was made of the accuracy of the death certificates regarding prostate cancer.
  • RESULTS: A total of 414 men were diagnosed with adenocarcinoma of the prostate.
  • Of these, 370 were alive at the time of diagnosis and stage could be determined.
  • Four stage groups were defined: focal incidental (n=50); localized (n=164); local advanced (n=32); and metastatic disease (n=124).
  • A total of 334 patients died during the follow-up period, of whom 168 (50%) died of prostate cancer.
  • Prostate cancer-specific survival at 10 and 15 years was 100% and 90.6%, respectively for focal incidental cancer; 73.1% and 60.8% for men with localized disease; 23.4% and 11.7% for local advanced disease; and 6.81% and 5.45% for metastatic disease.
  • A Cox multivariate analysis showed age, stage and Gleason score to be independent predictors of prostate cancer death.
  • Death certificates were judged to be accurate with regard to prostate cancer in nearly all instances (96%).
  • CONCLUSIONS: During an extended follow-up period, half of all patients with prostate cancer died from the disease.
  • However, a higher stage and grade were associated with substantial prostate cancer mortality.
  • Death certificates were accurate as far as prostate cancer was concerned.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916765.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


25. Bantis A, Gonidi M, Athanassiades P, Tsolos Ch, Liossi A, Aggelonidou E, Athanassiadou AM, Petrakakou E, Athanassiadou P: Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors. J Exp Clin Cancer Res; 2005 Jun;24(2):273-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors.
  • The ability to accurately predict tumor behavior and patient survival is a problem in managing patients with prostate cancer.
  • DNA ploidy provides important information for the evaluation of the prognosis of prostate cancer.
  • The aim of this study was to investigate the DNA ploidy in imprints from prostate adenocarcinomas in a group of 70 patients in relation to Gleason score, tumor differentiation, stage and PSA serum levels.
  • A statistically significant difference was found between DNA aneuploidy and increased pretreatment PSA serum levels (>4 ng/ml) (p<0.001), as well as between ploidy pattern and stage of the disease (p<0.001).
  • Our results conclude that DNA ploidy status appears to be an additional marker in the field of prognosis of prostatic adenocarcinoma and could provide useful information on the potential behavior of prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. DNA / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110761.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


26. Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL: Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol; 2010 Dec;184(6):2303-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.
  • In a population based cancer registry we identified a large group of patients with ductal carcinoma to characterize the impact of the ductal subtype on presentation and survival in men with prostate cancer.
  • MATERIALS AND METHODS: We used a national cancer registry to identify incident cases of ductal and acinar adenocarcinoma from 1996 to 2006.
  • Prostate specific antigen values were available for 2004 to 2006 and used to assess differences in Gleason grade and serum prostate specific antigen between ductal and acinar cancer cases at diagnosis.
  • Ductal histology was associated with a 30% decrease in geometric mean prostate specific antigen (adjusted coefficient 0.7, 95% CI 0.6-0.8) and more than 2-fold increased odds of prostate specific antigen less than 4.0 ng/ml (OR 2.4, 95% CI 1.4-4.0) independent of other clinicopathological variables.
  • CONCLUSIONS: In what is to our knowledge the largest series of this histological subtype ductal cancer cases were more likely to present with advanced stage cancer and lower prostate specific antigen, suggesting that timely disease detection is a significant challenge.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1471-9 [10584700.001]
  • [Cites] BJU Int. 2010 Feb;105(4):476-80 [19709071.001]
  • [Cites] Cancer. 2002 May 15;94(10):2610-7 [12173328.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Cancer. 1973 Aug;32(2):402-9 [4124700.001]
  • [Cites] J Urol. 1979 Mar;121(3):303-5 [219263.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Cancer. 1987 May 15;59(10):1803-9 [3030528.001]
  • [Cites] Prostate. 1987;10(2):123-31 [2436204.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Histopathology. 1996 Jul;29(1):11-9 [8818689.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] Am J Surg Pathol. 1999 Jul;23(7):781-5 [10403300.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):302-9 [16891207.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):198-204 [17171704.001]
  • [Cites] Pathology. 2007 Oct;39(5):476-81 [17886096.001]
  • [Cites] Urol Oncol. 2008 Jul-Aug;26(4):368-71 [18367098.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2872-80 [19402048.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):281-5 [20004936.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):552-7 [11939729.001]
  • (PMID = 20952027.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009168-30; United States / NCI NIH HHS / CA / T32 CA009168; United States / NCI NIH HHS / CA / T32 CA009168-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS294511; NLM/ PMC3111052
  •  go-up   go-down


27. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW: Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis; 2006;9(3):254-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
  • Between 1970 and 1983, 159 patients underwent RP for newly diagnosed adenocarcinoma of the prostate and were found to have positive surgical margins, extracapsular extension and/or seminal vesicle invasion.
  • The RT group generally received 45-50 Gy to the whole pelvis, then a boost to the prostate bed (total dose of 55-65 Gy).
  • In contrast to recurrences, nearly half of deaths from prostate cancer occurred more than 10 years after treatment.
  • Deaths from prostate cancer represented 55% of all deaths in these patients.
  • Despite its long natural history, death from prostate cancer was the most common cause of mortality in this population with locally advanced tumors, reflecting the need for more effective therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880828.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


29. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR: Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res; 2008 Aug;6(8):1365-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model.
  • We analyzed DNA methyltransferase (Dnmt) protein expression and DNA methylation patterns during four progressive stages of prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP) model, including prostatic intraepithelial neoplasia, well-differentiated tumors, early poorly differentiated tumors, and late poorly differentiated tumors.
  • Parallel gene expression and DNA methylation analyses suggests that gene overexpression precedes downstream hypermethylation during prostate tumor progression.
  • In contrast to gene hypermethylation, genomic DNA hypomethylation, including hypomethylation of repetitive elements and loss of genomic 5-methyldeoxycytidine, occurred in both early and late stages of prostate cancer.
  • In summary, our data reveal the relative timing of and relationship between key alterations of the DNA methylation pathway occurring during prostate tumor progression in an in vivo model system.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):58-65 [12203790.001]
  • [Cites] Clin Lung Cancer. 2006 Jul;8(1):39-44 [16870044.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12253-8 [14519846.001]
  • [Cites] Genomics. 2006 May;87(5):572-9 [16487676.001]
  • [Cites] Mol Cancer Res. 2006 Jan;4(1):1-8 [16446401.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11659-67 [17178860.001]
  • [Cites] J Pathol. 2007 Feb;211(3):269-77 [17139617.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2136-43 [17404097.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3796-802 [17606710.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1757-69 [17907813.001]
  • [Cites] Epigenetics. 2007 Sep;2(3):161-72 [17965620.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4173-82 [18519676.001]
  • [Cites] Prostate. 2000 May 15;43(3):233-42 [10797499.001]
  • [Cites] Nucleic Acids Res. 2000 May 15;28(10):2108-13 [10773079.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):299-304 [11531283.001]
  • [Cites] Mol Carcinog. 2002 Mar;33(3):163-71 [11870882.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Nucleic Acids Res. 1976 Sep;3(9):2303-8 [987581.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):531-6 [9641498.001]
  • [Cites] Trends Genet. 1999 Jan;15(1):34-7 [10087932.001]
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):31-6 [15588853.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Oct 7;335(4):1211-6 [16115613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):385-92 [16397253.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • (PMID = 18667590.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA128062-01; United States / NCI NIH HHS / CA / R21 CA121216; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R21 CA128062; United States / NCI NIH HHS / CA / R21 CA128062-02; United States / NCI NIH HHS / CA / NIH 5T32CA009072; United States / NCI NIH HHS / CA / CA128062-02; United States / NCI NIH HHS / CA / NIH R21 CA128062; United States / NCI NIH HHS / CA / CA128062-01; United States / NCI NIH HHS / CA / T32 CA009072
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channels, N-Type; 0 / Calcium Channels, P-Type; 0 / Calcium Channels, Q-Type; 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / voltage-dependent calcium channel (P-Q type); EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase
  • [Other-IDs] NLM/ NIHMS182572; NLM/ PMC2835734
  •  go-up   go-down


30. Sciarra A, Lichtner M, Autran GA, Mastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F: Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate; 2007 Jan 1;67(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
  • PURPOSE: We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.
  • METHODS: Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease.
  • RESULTS: We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002).
  • Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively).
  • CONCLUSIONS: We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Dendritic Cells / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17075798.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol; 2007 Feb;211(3):269-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
  • Promoter CpG island hypermethylation is an important carcinogenic event in prostate adenocarcinoma.
  • The present study evaluated CpG island loci hypermethylation and LINE-1 and Alu repeat hypomethylation in prostate adenocarcinoma, analysed the relationship between them, and correlated these findings with clinicopathological features.
  • We examined 179 cases of prostate adenocarcinoma and 30 cases of benign prostate hypertrophy for the methylation status of 22 CpG island loci and the methylation levels of LINE-1 and Alu repeats using methylation-specific polymerase chain reaction and combined bisulphite restriction analysis, respectively.
  • Except for the last four CpG island loci, hypermethylation of each of the remaining 12 CpG island loci displayed a close association with one or more of the prognostic parameters (ie preoperative serum prostate specific antigen level, Gleason score sum, and clinical stage).
  • Prostate adenocarcinoma with hypermethylation of each of ASC, COX2, RARB, TNFRSF10C, MDR1, TIG1, RBP1, NEUROG1, RASSF1A, and GSTP1 showed a significantly lower methylation level of Alu or LINE-1 than prostate adenocarcinoma without hypermethylation.
  • [MeSH-major] Adenocarcinoma / metabolism. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Prostatic Neoplasms / metabolism


32. Kamiya N, Suzuki H, Kawamura K, Imamoto T, Naya Y, Tochigi N, Kakuta Y, Yamaguchi K, Ishikura H, Ichikawa T: Neuroendocrine differentiation in stage D2 prostate cancers. Int J Urol; 2008 May;15(5):423-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiation in stage D2 prostate cancers.
  • OBJECTIVES: Chromogranin A (CgA) and neuro-specific enolase (NSE) are gaining acceptance as markers of several types of neuroendocrine tumors and the concentration of CgA and NSE have been reported to be elevated in relation to neuroendocrine differentiation of prostate cancer.
  • The aim of the present study was to examine the correlation between the immunohistochemical (IHC) findings and serum value for CgA and NSE in untreated stage D(2) prostate cancer patients.
  • METHODS: Immunohistochemistry was carried out using antibodies against CgA and NSE in 58 patients and, pretreatment serum CgA and NSE levels were measured by monoclonal immunoradiometric assay in 18 patients with stage D(2) prostate cancer treated by androgen ablation.
  • We examined the relationship of the pretreatment serum level to IHC findings for CgA and NSE in prostate cancer patients to clinicopathological parameters, and prognosis.
  • We divided stage D(2) patients into three groups according to IHC positivity of CgA and NSE.
  • Multivariate analysis of cause-specific survivals in patients with stage D(2) prostate cancer demonstrated that strong IHC stain was considered as independent variable associated with greater risk of death (P = 0.0142).
  • CONCLUSION: Neuroendocrine differentiation in stage D(2) prostate cancer has attracted considerable attention as a potentially findings prognosis.
  • Thus, CgA had a stronger relationship between serum levels and IHC positivity in contrast to NSE, suggesting clinical usefulness as a tumor marker in predicting the extent of neuroendocrine differentiation in prostate cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Chromogranin A / blood. Phosphopyruvate Hydratase / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452460.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Chromogranin A; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


33. Furusato B, Koff S, McLeod DG, Sesterhenn IA: Sarcoidosis of the prostate. J Clin Pathol; 2007 Mar;60(3):325-6
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis of the prostate.
  • A 55-year-old African-American man with clinical stage T1c prostate cancer underwent prostatectomy.
  • [MeSH-minor] Adenocarcinoma / complications. Humans. Incidental Findings. Male. Middle Aged. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1974 Mar;29(3):247-51 [4830144.001]
  • [Cites] Am J Clin Pathol. 1949 Aug;19(8):725-49 [18135500.001]
  • [Cites] Br J Urol. 1993 Oct;72(4):462-4 [8261305.001]
  • [Cites] J Urol. 1980 Jan;123(1):133-4 [7351709.001]
  • (PMID = 17347286.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 5
  • [Other-IDs] NLM/ PMC1860563
  •  go-up   go-down


34. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R: Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res; 2007 Nov 15;67(22):11083-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
  • Herein, for the first time, we evaluated the chemopreventive efficacy of dietary silibinin against prostate cancer (PCa) growth and progression in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice from two different genetic backgrounds [C57BL/6 (TRAMP) x FVB; C57BL/6 (TRAMP) x C57BL/6].
  • Silibinin-fed groups had a lower tumor grade and higher incidence of prostatic intraepithelial neoplasia (PIN) at the expense of a strong decrease in adenocarcinoma incidence.
  • Prostate tissue showed a 47% (P < 0.001) decrease in proliferating cell nuclear antigen (PCNA)-positive cells and an approximately 7-fold (P < 0.001) increase in apoptotic cells at the highest silibinin dose.
  • Together, these findings suggest that oral silibinin blocks PCa growth and progression at PIN stage in TRAMP mice via modulation of tumor IGF-IGFBP-3 axis and cell cycle regulation, and therefore it has practical and translational potential in suppressing growth and neoplastic conversion of PIN to PCa in humans.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenocarcinoma / therapy. Prostatic Neoplasms / prevention & control. Prostatic Neoplasms / therapy
  • [MeSH-minor] Animals. Anticarcinogenic Agents / therapeutic use. Antioxidants / therapeutic use. Disease Models, Animal. Disease Progression. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Phosphorylation. Prostate / drug effects. Silymarin / therapeutic use. Species Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006855.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100938; United States / NCI NIH HHS / CA / R01 CA102514; United States / NCI NIH HHS / CA / R01 CA104286; United States / NCI NIH HHS / CA / R01 CA84296
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Silymarin; 4RKY41TBTF / silybin
  •  go-up   go-down


35. Amirghofran Z, Monabati A, Gholijani N: Apoptosis in prostate cancer: bax correlation with stage. Int J Urol; 2005 Apr;12(4):340-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in prostate cancer: bax correlation with stage.
  • BACKGROUND: Dysregulation of apoptosis may contribute to the process of prostate tumorigenesis by reducing the rate of cell death.
  • The aim of the present study is to examine apoptosis and related regulatory molecular markers in a group of Iranian patients with prostate cancer.
  • METHODS: Paraffin-embedded tissues from 50 patients of prostate carcinoma were examined for the expression of bcl-2 antiapoptotic and bax proapoptotic markers and also proliferation marker, Ki-67, by immunohistochemistry.
  • Correlation between apoptotic index, proliferation index and bcl-2 and bax expression with stage, pathological grade and Gleason score was determined.
  • RESULTS: Apoptosis was detected in 12% of prostate cancers.
  • We found a significant correlation between bax expression and stage of carcinoma (r = 0.388, P = 0.031), but not with the apoptosis index, suggesting the presence of a non-functional bax protein or the role of other proapoptotic molecules.
  • Bax expression may be a useful marker for prognosis of prostate cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948719.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


36. Kinney SR, Moser MT, Pascual M, Greally JM, Foster BA, Karpf AR: Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol Cell Biol; 2010 Sep;30(17):4159-74
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer.
  • Previous studies have shown that tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model is characterized by global DNA hypomethylation initiated during early-stage disease and locus-specific DNA hypermethylation occurring predominantly in late-stage disease.
  • Here, we utilized Dnmt1 hypomorphic alleles to examine the role of Dnmt1 in normal prostate development and in prostate cancer in TRAMP.
  • Prostate tissue morphology and differentiation status was normal in Dnmt1 hypomorphic mice, despite global DNA hypomethylation.
  • Thus, Dnmt1 has tumor suppressor activity in early-stage prostate cancer, and oncogenic activity in late stage prostate cancer and metastasis.
  • Consistent with the biological phenotype, epigenomic studies revealed that TRAMP; Dnmt1 hypomorphic mice show dramatically reduced CpG island and promoter DNA hypermethylation in late-stage primary tumors compared to control mice.
  • Taken together, the data reveal a crucial role for Dnmt1 in prostate cancer and suggest that Dnmt1-targeted interventions may have utility specifically for advanced and/or metastatic prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Urol. 2009 Aug;182(2):756-61 [19539327.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):751-7 [11259619.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7500-6 [11096088.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 28;287(3):705-13 [11563853.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1296-9 [11888894.001]
  • [Cites] Mol Cell Biol. 2002 May;22(9):2906-17 [11940649.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5361-79 [12154399.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5496-503 [12154410.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Science. 2003 Apr 18;300(5618):455 [12702868.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Dev Biol. 2004 Apr 15;268(2):403-15 [15063176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(11):3389-93 [6203119.001]
  • [Cites] Cell. 1992 Jun 12;69(6):915-26 [1606615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Cell. 1995 Apr 21;81(2):197-205 [7537636.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7327-35 [10523621.001]
  • [Cites] Acta Endocrinol (Copenh). 1965 May;49:145-54 [14277117.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6667-75 [16007164.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):385-92 [16397253.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):682-92 [16423997.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1105-13 [16424047.001]
  • [Cites] Genome Res. 2006 Aug;16(8):1046-55 [16809668.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(19):7077-85 [16980612.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3089-103 [17085482.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11659-67 [17178860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2136-43 [17404097.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(12):3829-39 [19386619.001]
  • [Cites] Prostate. 2009 Sep 1;69(12):1312-24 [19444856.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Sep 25;387(3):611-6 [19632198.001]
  • [Cites] Endocrinology. 2009 Sep;150(9):3991-4002 [19520778.001]
  • [Cites] Surg Oncol. 2009 Sep;18(3):203-12 [19398328.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Dec;2(12):1065-75 [19934341.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):796-804 [17534929.001]
  • [Cites] Anticancer Drugs. 2007 Nov;18(10):1157-64 [17893516.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2855-63 [17636035.001]
  • [Cites] Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5 [18432778.001]
  • [Cites] Bioinformatics. 2008 May 1;24(9):1161-7 [18353789.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4173-82 [18519676.001]
  • [Cites] Mol Cancer Res. 2008 Aug;6(8):1365-74 [18667590.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9358-66 [19010910.001]
  • [Cites] Gene. 2009 Feb 15;431(1-2):55-60 [19027835.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):240-5 [19002169.001]
  • [Cites] Cancer Sci. 2009 Jul;100(7):1186-91 [19432896.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • (PMID = 20584988.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21CA128062; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R21 CA128062; United States / NCI NIH HHS / CA / R21 CA128062-02; United States / NCI NIH HHS / CA / CA128062-02; United States / NCI NIH HHS / CA / 5T32CA009072; United States / NCI NIH HHS / CA / T32 CA009072
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1
  • [Other-IDs] NLM/ PMC2937561
  •  go-up   go-down


37. Veshapidze N, Chigogidze T, Managadze L, Gabunia N, Kotrikadze N: Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy. Georgian Med News; 2007 Dec;(153):11-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
  • The changes of electrophoretic mobility of erythrocytes in the practically healthy men and in men with metastatic prostate cancer before and after castration were studied.
  • Investigation revealed, that the level of electrophoretic mobility of erythrocytes was decreased in the blood of metastatic prostate cancer patients (before castration), as compared with control group and with post operational period data.
  • It was found, that during the malignant adenocarcinoma of prostate (before and after surgery) pathological changes in organism effect erythrocytes superficial membranes and alter their electrical and structural parameters.
  • Probably, that is one of the reasons of considerable decrease of erythrocytes electrophoretic mobility in patients with metastatic prostate adenocarcinoma (before castration).
  • Also, comparative normalization of erythrocytes electrophoretic mobility after castration and its approximation to the control group on this stage (4-6 months after castration) may be the reason that induces partial restoration of organism homeostasis.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Erythrocytes / metabolism. Erythrocytes / ultrastructure. Orchiectomy / methods. Postoperative Care. Preoperative Care. Prostatic Neoplasms / secondary. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250488.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


38. Spencer BA, Miller DC, Litwin MS, Ritchey JD, Stewart AK, Dunn RL, Gay EG, Sandler HM, Wei JT: Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol; 2008 Aug 1;26(22):3735-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in quality of care for men with early-stage prostate cancer.
  • METHODS: We sampled early-stage prostate cancer cases diagnosed in 2000 through 2001 from the American College of Surgeons National Cancer Data Base and explicitly reviewed medical records from 2,775 men (weighted total = 55,160 cases) treated with radical prostatectomy or external-beam radiation therapy.
  • CONCLUSION: The significant and unwarranted variations observed for these quality indicators by census division and hospital type illustrate the inconsistencies in prostate cancer care and represent potential targets for quality improvement.
  • [MeSH-major] Adenocarcinoma / therapy. Healthcare Disparities. Prostatectomy / standards. Prostatic Neoplasms / therapy. Quality of Health Care / standards

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / NIH-1-T-32 DKO7782; United States / NCI NIH HHS / PC / PC040167
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol; 2005 Feb 1;23(4):800-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
  • PURPOSE: To update the effect of immediate androgen suppression in conjunction with standard external-beam irradiation versus radiation alone on a group of histologically lymph node-positive patients with adenocarcinoma of the prostate.
  • MATERIALS AND METHODS: A national prospective randomized trial (Radiation Therapy Oncology Group 85-31) of standard external-beam irradiation plus immediate androgen suppression versus external-beam irradiation alone was initiated in 1985 for patients with locally advanced adenocarcinoma of the prostate.
  • RESULTS: With a median follow-up of 6.5 years for all patients and 9.5 years for living patients, estimated progression-free survival with prostate-specific antigen (PSA) level less than 1.5 ng/mL at 5 and 9 years was 54% and 33%, respectively, for patients who received immediate LHRH agonist versus 10% [corrected] and 4% for patients who received radiation alone with hormonal manipulation instituted at time of relapse (P < .0001).
  • CONCLUSION: Pending the results of randomized trials, patients with adenocarcinoma of the prostate who have pathologically involved pelvic lymph nodes (pathologic node-positive or clinical stage D1) should be considered for external-beam irradiation plus immediate hormonal manipulation rather than radiation alone with hormone manipulation at the time of relapse.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Goserelin / therapeutic use. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2005 Dec 1;23(34):8921
  • (PMID = 15681524.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0F65R8P09N / Goserelin
  •  go-up   go-down


40. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R: Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol; 2006 Nov;169(5):1812-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.
  • In prostate adenocarcinoma, 39 microRNAs are up-regulated, and six microRNAs are down-regulated.
  • From a gene array analysis of 16 normal prostate tissue samples, 64 organ-confined, and four metastatic prostate adenocarcinomas, we identified an up-regulation of major components of the microRNA machinery, including Dicer, in metastatic prostate adenocarcinoma.
  • Immunohistochemical studies on a tissue microarray consisting of 232 prostate specimens confirmed up-regulation of Dicer in prostatic intraepithelial neoplasia and in 81% of prostate adenocarcinoma.
  • The increased Dicer level in prostate adenocarcinoma correlated with clinical stage, lymph node status, and Gleason score.
  • Western blot analysis of benign and neoplastic prostate cell lines further confirmed Dicer up-regulation in prostate adenocarcinoma.
  • Dicer up-regulation may explain an almost global increase of microRNA expression in prostate adenocarcinoma.
  • The presence of up-regulated microRNA machinery may predict the susceptibility of prostate adenocarcinoma to RNA interference-based therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. DEAD-box RNA Helicases / metabolism. Endoribonucleases / metabolism. MicroRNAs / metabolism. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / pathology. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Epithelium / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Prostate / cytology. Prostate / enzymology. Prostate / pathology. Ribonuclease III

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):784-91 [15247924.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):552-4 [14697225.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]
  • [Cites] Nat Neurosci. 2004 Feb;7(2):113-7 [14703574.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1425-35 [14699070.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 1996;30(2):201-5 [8875201.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1048-53 [15516998.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Cancer Gene Ther. 2005 Mar;12(3):217-27 [15550938.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):561-71 [15845026.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Curr Opin Struct Biol. 2005 Jun;15(3):331-41 [15925505.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] J Exp Med. 2005 Jul 18;202(2):261-9 [16009718.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):740-4 [15973356.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):852-7 [16230228.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):688-93 [16271080.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):926-34 [15956982.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2149-55 [16289642.001]
  • [Cites] Differentiation. 2005 Dec;73(9-10):463-73 [16351690.001]
  • [Cites] Genes Dev. 2005 Dec 15;19(24):2979-90 [16357216.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):4-9 [16361094.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):179-86 [16432177.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):776-80 [16495913.001]
  • [Cites] Genome Biol. 2006;7(3):210 [16584538.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Prostate. 2002 May 1;51(2):98-107 [11948964.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):177-81 [12127403.001]
  • [Cites] Chin Med J (Engl). 2002 Apr;115(4):571-5 [12133301.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1833-7 [12193640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16648-53 [12482946.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Urology. 2003 Aug;62(2):378-84 [12893368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • (PMID = 17071602.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; EC 3.1.- / Endoribonucleases; EC 3.1.26.3 / DICER1 protein, human; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ PMC1780192
  •  go-up   go-down


41. Nakanishi S, Hatayama T: [Adenocarcinoma of the prostate associated with anti Jo-1 antibody positive polymyositis]. Hinyokika Kiyo; 2006 Apr;52(4):289-91
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the prostate associated with anti Jo-1 antibody positive polymyositis].
  • A 76-year-old male was hospitalized with elevation of prostate specific antigen.
  • Adenocarcinoma was classified as Gleason score 8 by needle biopsy of the prostate and the stage of the prostate carcinoma was cT3aN1M0.
  • [MeSH-major] Adenocarcinoma / complications. Antibodies, Antinuclear / immunology. Polymyositis / immunology. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Polymyositis.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686358.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Antinuclear; 0 / Jo-1 antibody; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


42. Brock M, Martin W, Sommerer F, Noldus J: [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?]. Urologe A; 2009 Jul;48(7):770-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].
  • [Transliterated title] Das duktale Adenokarzinom der Prostata mit Blasenhalsinfiltration. Heilung durch radikale Zystektomie und antiandrogene Therapie?
  • Ductal adenocarcinoma of the prostate is a rare entity.
  • The lack of correlation between the prostate-specific antigen value and the tumor stage, as well as early dissemination, are major differences from acinar cancer.
  • Due to a lack of early symptoms, the tumor is often found in an advanced stage.
  • We report the case of a 64-year-old man with ductal prostate cancer who underwent radical cystectomy followed by androgen deprivation therapy.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352617.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


43. Kawakami S, Hyochi N, Yonese J, Yano M, Fujii Y, Kageyama Y, Fukui I, Kihara K: Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol; 2006 Apr;11(2):127-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer.
  • BACKGROUND: Although an increasing number of men present with stage T1c prostate cancer, the optimal biopsy strategy for detecting stage T1c disease still remains to be defined.
  • The aim of this study was to explore an efficient first-time biopsy scheme for detecting stage T1c and T2 prostate cancer.
  • METHODS: A transrectal ultrasound-guided systematic three-dimensional 26-core (3D26) biopsy comprising 12 transrectal and 14 transperineal sampling sites was performed in 321 men with median prostate-specific antigen (PSA) level of 6.0 ng/ml in the first-time biopsy setting.
  • RESULTS: Prostate cancer was detected in 109 of the 321 men (34%) with a major complication rate of 0.6%.
  • Recursive partitioning revealed that a three-dimensional 14-core (transrectal 8-core plus transperineal 6-core) and a three-dimensional 8-core (transrectal 4-core plus transperineal 4-core) biopsies could detect more than 95% of stage T1c and T2 cancers with a minimum number of cores, respectively.
  • CONCLUSION: We propose a three-dimensional 14-core and a three-dimensional 8-core biopsy as efficient first-time biopsy schemes to detect stage T1c and T2 prostate cancer, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Prostatic Neoplasms / pathology
  • [MeSH-minor] Digital Rectal Examination. Humans. Logistic Models. Male. Neoplasm Staging. Perineum. Prostate-Specific Antigen / blood. Rectum

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622747.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


44. Sung MT, Eble JN, Cheng L: Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. Pathology; 2006 Aug;38(4):309-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma.
  • METHODS: Between 2000 and 2003, 313 consecutive patients underwent radical prostatectomy for clinically localised prostate cancer in the Indiana University Hospital.
  • Other pathological characteristics of prostate cancer were also assessed and clinical data were gathered by a review of patient charts.
  • None of these 313 radical prostatectomy specimens revealed any adipose tissue components within the most peripheral boundary of normal prostatic acini in the prostate.
  • CONCLUSIONS: We found no evidence of intraprostatic fat and our findings suggest that, at best, the occurrence of fat within the prostate is of extreme rarity.
  • Accordingly, the finding of carcinoma invading adipose tissue in needle biopsies should continue to be considered as extraprostatic extension and stage pT3a assigned.
  • [MeSH-major] Adenocarcinoma / pathology. Adipose Tissue / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916718.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Segawa N, Inamoto T, Ibuki N, Mizutani Y, Azuma H, Tsuji M, Katsuoka Y: [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report]. Hinyokika Kiyo; 2010 Jan;56(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
  • A case of neuroendocrine (NE) differentiated prostate cancer is reported herein, which was progressed with NE differentiation during hormonal treatment in adenocarcinoma of the prostate.
  • A 65-year-old man was admitted to our department with increased serum prostate specific antigen (PSA) (150 ng/ml).
  • A prostate biopsy was performed and histological examinations indicated poorly differentiated adenocarcinoma with a Gleason score of 5 + 4 = 9.
  • The clinical stage was T3bN0M1b and hormonal therapy using leuprorelin was started.
  • Computed tomography (CT) demonstrated enlargement of the prostate and swelling of multiple pelvic lymph nodes.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents, Hormonal / therapeutic use. Leuprolide / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Humans. Male. Phosphopyruvate Hydratase / analysis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104011.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 26
  •  go-up   go-down


46. Liu S, Lü JJ, Fu Q, Zhang H, Gao DX, Liu Z: [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]. Zhonghua Nan Ke Xue; 2010 May;16(5):415-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer].
  • OBJECTIVE: To evaluate the roles of total prostate specific antigen (tPSA), PSA density (PSAD) and biopsy Gleason score in predicting the pathologic stage of prostate cancer.
  • METHODS: We retrospectively analyzed the clinical data of 124 cases of pathologically confirmed prostate adenocarcinoma, and divided them into Groups A (n=48) and B (n=76) based on the results of bone scanning, CT, MRI, tPSA, PSAD and postoperative biopsy Gleason score, the former with extraprostatic infiltration or distant metastasis, while the latter without.
  • We compared the above parameters between the two groups, screened the main factors that influenced the pathologic staging of prostate cancer by multivariate logistic regression analysis, and appraised the value of each of the parameters in predicting the pathologic stage of prostate cancer with a relative operating characteristic (ROC) curve.
  • Multivariate logistic regression analysis showed that only tPSA could predict the pathologic stage of localized prostate cancer.
  • CONCLUSION: Total PSA remains a valuable predictor of the pathologic stage of prostate cancer, and its combination with Gleason score can further improve the predictive accuracy and contribute much to the treatment and prognosis of the disease.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Prostate / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684321.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


47. Dall'Oglio MF, Crippa A, Oliveira LC, Neves Neto JF, Leite KR, Srougi M: Prediction of pathological stage in prostate cancer through the percentage of involved fragments upon biopsy. Int Braz J Urol; 2005 Sep-Oct;31(5):445-51
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of pathological stage in prostate cancer through the percentage of involved fragments upon biopsy.
  • INTRODUCTION: The need for defining the extension of disease in patients undergoing radical prostatectomy due to prostate adenocarcinoma is a relevant factor cure in such individuals.
  • In order to identify a new independent preoperative factor for predicting the extension of prostate cancer, we assessed the role of the percentage of positive fragments upon biopsy.
  • MATERIALS AND METHODS: A retrospective study compared the percentage of positive fragments on biopsy with the extension of disease as defined by the pathological examination of the surgical specimen from 898 patients undergoing radical prostatectomy due to clinically localized prostate cancer.
  • CONCLUSION: the percentage of positive fragments is an independent factor for predicting the pathological stage of prostate adenocarcinoma, and the number of removed fragments is not related to the extension of the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255790.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


48. White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS: Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol; 2008 Dec;180(6):2409-13; discussion 2414
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
  • PURPOSE: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma.
  • MATERIALS AND METHODS: The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years.
  • Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes.
  • CONCLUSIONS: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Quality of Life. Registries

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930270.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M: A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int; 2006 Mar;97(3):644-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma.
  • OBJECTIVE: To assess the immunoexpression of p21 and p27 proteins in consecutive areas of benign glands, prostatic intraepithelial neoplasia (PIN) and prostate adenocarcinoma.
  • PATIENTS AND METHODS: Tissue from 91 patients who had a radical prostatectomy was assessed by immunohistochemistry to evaluate the expression of p21 and p27 in adjacent areas of benign glands, PIN and prostate adenocarcinoma.
  • The results were correlated with various clinicopathological variables, e.g. age, total prostate-specific antigen level, tumour stage, Gleason score, surgical margin involvement, extraprostatic extension, seminal vesicle invasion, and perineural invasion.
  • The decline in p27 with advancing age in tumour and PIN areas may be a possible explanation of the greater frequency of prostate adenocarcinoma in older men.
  • [MeSH-major] Adenocarcinoma / chemistry. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Neoplasm Proteins / analysis. Prostatic Intraepithelial Neoplasia / chemistry. Prostatic Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469041.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


50. Henrique R, Jerónimo C, Hoque MO, Nomoto S, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D: MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev; 2005 May;14(5):1274-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
  • Although in normal prostate tissue zinc levels are high, there is a marked decrease in prostate cancer.
  • Metallothioneins control the bioavailability of zinc and one isoform, MT1G, was reported down-regulated in prostate cancer.
  • Here, we investigated whether promoter methylation might cause MT1G silencing in prostate cancer.
  • PATIENTS AND METHODS: The MT1G promoter was assessed by quantitative methylation-specific PCR on prospectively collected tissue samples from 121 patients with prostate cancer, 39 paired high-grade prostatic intraepithelial neoplasias (HGPIN), 29 patients with benign prostatic hyperplasia, 13 normal prostate tissue samples from cystoprostatectomy specimens, and prostate cancer cell lines.
  • RESULTS: MT1G promoter hypermethylation was found in 29 of 121 prostate cancer, 5 of 39 HGPIN, 3 of 29 benign prostatic hyperplasia, and 0 of 13 normal prostate tissue samples.
  • Methylation levels were found to correlate with tumor stage but not with Gleason grade.
  • MT1G hypermethylation was more frequent in prostate cancer that spread beyond the prostate capsule.
  • All prostate cancer cell lines tested showed MT1G promoter methylation, but no differences in expression were apparent after demethylation.
  • CONCLUSIONS: Our findings suggest that MT1G promoter methylation is associated with tumor aggressiveness in prostate cancer and it might be a marker of locally advanced disease.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Analysis of Variance. Biomarkers, Tumor / blood. Cell Line, Tumor. Cell Proliferation. Disease Progression. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. RNA. Zinc / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894685.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 63231-63-0 / RNA; 9038-94-2 / Metallothionein; J41CSQ7QDS / Zinc
  •  go-up   go-down


51. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol; 2010 Mar 01;28(7):1106-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
  • PURPOSE To test the hypothesis that increasing radiation dose delivered to men with early-stage prostate cancer improves clinical outcomes.
  • PATIENTS AND METHODS Men with T1b-T2b prostate cancer and prostate-specific antigen </= 15 ng/mL were randomly assigned to a total dose of either 70.2 Gray equivalents (GyE; conventional) or 79.2 GyE (high).
  • CONCLUSION This randomized controlled trial shows superior long-term cancer control for men with localized prostate cancer receiving high-dose versus conventional-dose radiation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):123-6 [11743288.001]
  • [Cites] J Urol. 1991 Nov;146(5):1313-6 [1719244.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):81-9 [8988730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304 [9788407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):553-61 [10524405.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1233-9 [16160131.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):475-87 [17482880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74 [17765406.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8 [18495377.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12 [7721636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):436-41 [12243819.001]
  • [Cites] J Urol. 2004 Jan;171(1):210-4 [14665878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33 [14697417.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] JAMA. 1979 May 4;241(18):1912-5 [107338.001]
  • [Cites] Biometrics. 1990 Mar;46(1):81-92 [2350572.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935-9 [1917622.001]
  • [CommentIn] J Clin Oncol. 2010 Mar 1;28(7):1087-9 [20124163.001]
  • (PMID = 20124169.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA021239; United States / NCI NIH HHS / CA / P01 CA21239; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2834463
  •  go-up   go-down


52. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE: Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol; 2009 Nov;93(2):185-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma.
  • BACKGROUND AND PURPOSE: To determine whether radical prostatectomy (RP) or intensity-modulated radiation therapy (IMRT) to > or =72 Gy, plus hormonal therapy if indicated, results in improved biochemical disease-free survival (BDFS) in localized prostate adenocarcinoma.
  • The patients were stratified into prognostic groups based on clinical stage, Gleason score, and pretreatment prostate-specific antigen (PSA).
  • Within the entire cohort, after adjustment for confounding variables, Gleason score (p<.001) and clinical stage (p<.001) predicted BDFS, but treatment modality (p=.06) did not.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease-Free Survival. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19800702.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


53. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M: Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):584-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
  • We characterized, at the mRNA and protein levels, the expression of VEGF-A and VEGF-D and their cognate receptors, VEGFR-1, VEGFR-2, and VEGFR-3 in early- and advanced-stage prostate cancer specimens.
  • EXPERIMENTAL DESIGN: The levels of VEGF-A and VEGF-D mRNA in early- and advanced-stage specimens were compared using an angiogenic gene array and were confirmed by quantitative real-time PCR.
  • Spatial expression of the proteins was evaluated using immunohistochemistry with fresh and archival tissues from benign prostatic hypertrophy specimens, early-stage prostate specimens, and advanced-stage metastatic specimens.
  • RESULTS: We observed that expression patterns of VEGF isotypes corresponded to the prostate cancer stage: high expression of angiogenic growth factor VEGF-A was observed in early-stage prostate specimens, whereas high expression of lymphangiogenic growth factor VEGF-D was associated with advanced-stage metastatic disease.
  • All VEGF receptors were present at variable levels in all specimens, but their activation states varied in a stage-specific manner.
  • VEGFR-1 and, to a limited extent, VEGFR-2 were activated in early-stage specimens, whereas VEGFR-2 and VEGFR-3 were activated in advanced-stage specimens.
  • CONCLUSIONS: Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neovascularization, Pathologic / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701844.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR 16460
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


54. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, Mukhtar H: Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res; 2009 Mar 15;15(6):1947-53
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease.
  • PURPOSE: We have shown previously that oral feeding of green tea polyphenols (GTP) to transgenic adenocarcinoma of the mouse prostate mice in a purely chemopreventive setting significantly inhibits prostate cancer development.
  • To translate this to a human situation, the present study was designed to identify the stage of prostate cancer that is most vulnerable to chemopreventive intervention by GTP.
  • EXPERIMENTAL DESIGN: GTP infusion (0.1% in drinking water) to transgenic adenocarcinoma of the mouse prostate was initiated at ages representing different stage of the disease: (a) 6 weeks (group 1, normal prostate), (b) 12 weeks (group 2, prostatic intraepithelial neoplasia), (c) 18 weeks (group 3, well-differentiated adenocarcinoma), and (b) 28 weeks (group 4, moderately differentiated adenocarcinoma).
  • At age 32 weeks, subsets of animals were evaluated by magnetic resonance imaging, ultrasound, and prostate weight and for serum insulin-like growth factor (IGF)-I/IGF binding protein-3 and IGF signaling.
  • CONCLUSIONS: Our studies indicate that chemopreventive potential of GTP decreases with advancing stage of the disease and underscore the need to design appropriate chemoprevention clinical trails.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2008 Sep 15;68(13):1477-86 [18618736.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):196-204 [18521193.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):60-7 [10585584.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2744-7 [10946875.001]
  • [Cites] Nature. 2001 May 17;411(6835):390-5 [11357148.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10350-5 [11504910.001]
  • [Cites] Prostate. 2002 Feb 1;50(2):112-8 [11816019.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1442-6 [12627508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):768-80 [14570043.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):130-5 [14618627.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):571-82 [15130283.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):823-9 [15386368.001]
  • [Cites] Mol Endocrinol. 1994 Feb;8(2):230-9 [8170479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1595-606 [9032287.001]
  • [Cites] J Natl Med Assoc. 1998 Nov;90(11 Suppl):S720-3 [9828589.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2203-9 [10232609.001]
  • [Cites] Eur Urol. 1999;35(5-6):370-6 [10325491.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):317-24 [10453274.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2217-24 [15358631.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8715-22 [15574782.001]
  • [Cites] Urol Oncol. 2005 Mar-Apr;23(2):108-13 [15869995.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1234-40 [16424063.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2500-5 [16510563.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1047-53 [16314398.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5611-4 [17020962.001]
  • [Cites] Chem Res Toxicol. 2007 Apr;20(4):583-5 [17362033.001]
  • [Cites] Life Sci. 2007 Jul 26;81(7):519-33 [17655876.001]
  • [Cites] Mol Biotechnol. 2007 Sep;37(1):52-7 [17914164.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1576-89 [17705241.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2193-203 [18006906.001]
  • [Cites] Chem Biol Interact. 2008 Jan 30;171(2):122-32 [17403520.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Eur Urol. 2008 Aug;54(2):472-3 [18406041.001]
  • [Cites] Pharm Res. 2008 Sep;25(9):2135-42 [18317887.001]
  • (PMID = 19276266.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P50 DK065303; United States / NIDDK NIH HHS / DK / P50 DK065303-01; United States / NCI NIH HHS / CA / R01 CA078809; United States / NCI NIH HHS / CA / R01 CA078809-10; United States / NCI NIH HHS / CA / R01 CA 78809; United States / NCI NIH HHS / CA / R01 CA120451-05; United States / NCI NIH HHS / CA / CA078809-10; United States / NCI NIH HHS / CA / R01 CA101039; United States / NCI NIH HHS / CA / R01 CA120451; United States / NCI NIH HHS / CA / R01 CA101039-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Phenols; 0 / Polyphenols; 0 / Tea; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ NIHMS251985; NLM/ PMC2991083
  •  go-up   go-down


55. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, Strange R, Kumar AP: 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):980-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
  • PURPOSE: 2-Methoxyestradiol, an estrogenic metabolite, is in clinical trials for the treatment of hormone-refractory prostate cancer.
  • EXPERIMENTAL DESIGN: Eight- and 24-week-old transgenic adenocarcinoma of mouse prostate (TRAMP) mice were fed a diet containing 50 mg 2-methoxyestradiol/kg body weight for 16 and 8 weeks, respectively.
  • Chemopreventive efficacy was evaluated by magnetic resonance imaging, determining the prostate-seminal vesicle complex volume and histologic analysis of prostate tumor or tissue.
  • Expression of TSG-6 was analyzed in a human tissue array containing different grades of prostate tumors.
  • RESULTS: Dietary administration of 2-methoxyestradiol prevented the development of preneoplastic lesions independent of progression stage.
  • TSG-6 was low or undetectable in prostate cancer cells (LNCaP, PC-3, and DU145) and TRAMP tumors but up-regulated in response to 2-methoxyestradiol.
  • Immunohistochemistry of the human prostate tumor array showed a decrease in TSG-6-positive cells with increasing grade relative to normal prostate (P = 0.0001).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / prevention & control. Cell Adhesion Molecules / physiology. Estradiol / analogs & derivatives. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467113.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA-054174-16; United States / NCI NIH HHS / CA / R21 CA 98744
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / TNFAIP6 protein, human; 0 / Tnfaip6 protein, mouse; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol
  •  go-up   go-down


56. Challagundla S, Gokden M, Viswamitra S, Kohli M: Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage. Clin Prostate Cancer; 2005 Sep;4(2):134-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage.
  • We report a case of orbital metastasis from a neuroendocrine dedifferentiated prostate cancer during progression from hormone-sensitive to hormone refractory stage.
  • A patient receiving androgen deprivation for hormone-sensitive prostate cancer presented with sudden-onset right-sided ptosis and an increasing serum prostate-specific antigen level.
  • Comparison of the metastatic histology with the original pathology confirmed a histologic change to poorly differentiated prostate adenocarcinoma with neuroendocrine features.
  • Because prostate cancer metastasis involves hematogenous and lymphatic routes, we also evaluated expression of the vascular endothelial growth factor (VEGF) and receptors (VEGFR-1, VEGFR-2, and VEGFR-3) in the metastatic deposit by immunohistochemistry.
  • We recommend a second biopsy of atypical prostate metastasis associated with sudden change to aggressive clinical behavior in order to evaluate for dedifferentiation features before planning appropriate treatment interventions especially in patients who are candidates for systemic chemotherapy.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197616.001).
  • [ISSN] 1540-0352
  • [Journal-full-title] Clinical prostate cancer
  • [ISO-abbreviation] Clin Prostate Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


57. Quan AL, Ciezki JP, Reddy CA, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, De Oreo G, Klein EA: Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology; 2006 Dec;68(6):1237-41
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate.
  • OBJECTIVES: To analyze whether prostate size affects biochemical relapse-free survival (bRFS).
  • All patients were treated with iodine-125 alone as the radiotherapeutic modality and had a minimum of four posttreatment prostate-specific antigen values.
  • The factors examined in the univariate and multivariate analyses predicting for bRFS included gland volume, patient age, initial prostate-specific antigen value, biopsy Gleason score, clinical stage, and postimplant dosimetric variables.
  • On separate multivariate analyses, only the pretreatment prostate width and volume significantly influenced bRFS favorably (P = 0.0069 and P = 0.0255, respectively).
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Brachytherapy / instrumentation. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169646.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


58. Gunia S, Koch S, May M, Dietel M, Erbersdobler A: Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Arch; 2009 May;454(5):573-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies.
  • Clinical management of incidental prostate cancer (IPC) remains challenging since its clinical course cannot be predicted by conventional histopathology.
  • Aiming to define predictive factors in IPC, we correlated the immunohistochemically detected expression of prostate-specific antigen (PSA), prostatic acid phosphatase (PSAP), alpha-methylacyl-CoA racemase (AMACR, p504s), and androgen receptor in transurethral resection specimens with Gleason scores and histologic staging on the corresponding radicals in a cohort of 54 patients (mean age, 65.9 years; range, 49-80 years).
  • Therefore, PSAP might be predictive of tumor stage in IPC and represent a valuable adjunct for clinical decisions in terms of individual therapeutic management.
  • [MeSH-major] Adenocarcinoma / enzymology. Prostate / enzymology. Prostatic Neoplasms / enzymology. Protein Tyrosine Phosphatases / metabolism. Transurethral Resection of Prostate
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Incidental Findings. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Prostate-Specific Antigen / metabolism. Prostatectomy. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301031.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


59. Harper CE, Patel BB, Wang J, Eltoum IA, Lamartiniere CA: Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate; 2007 Oct 1;67(14):1576-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
  • BACKGROUND: Prostate cancer (PCa) is the second leading cause of cancer-related death in men in the United States.
  • Green tea polyphenols, one such agent, has been shown to be chemopreventive in skin, breast, and prostate cancers.
  • We hypothesized that Epigallocatechin-3-Gallate (EGCG), the major polyphenol found in green tea, will exert its chemopreventive effect in the prostate via regulation of sex steroid receptor, growth factor-signaling, and inflammatory pathways.
  • METHODS: Five-week-old male TRAMP (Transgenic Adenocarcinoma Mouse Prostate) offspring were fed AIN-76A diet and 0.06% EGCG in tap water.
  • RESULTS: EGCG, inhibited early but not late stage PCa in the current study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticarcinogenic Agents / pharmacology. Catechin / analogs & derivatives. MAP Kinase Signaling System. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Insulin-Like Growth Factor I / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Prostate / drug effects. Prostate / pathology. Receptor, IGF Type 1 / drug effects. Receptor, IGF Type 1 / metabolism. Receptors, Androgen / drug effects. Receptors, Androgen / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705241.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 47888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Receptors, Androgen; 67763-96-6 / Insulin-Like Growth Factor I; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


60. Mhawech-Fauceglia P, Smiraglia DJ, Bshara W, Andrews C, Schwaller J, South S, Higgs D, Lele S, Herrmann F, Odunsi K: Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):571-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma.
  • The aim of this study was to determine the role of prostate-specific membrane antigen (PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore whether its down-regulation could be due to epigenetic mechanism.
  • Higher PSMA mRNA levels were associated with stage I (P = 0.046) and PSMA protein intensity by immunohistochemistry (P = 0.032).
  • PSMA was methylated in prostate cell lines (DU145 and PC3) and endometrial cell lines.
  • In summary, (a) PSMA is underexpressed in advanced stage EAC, (b) loss of PSMA expression can be considered as a prognostic marker in patients with EAC, and (c) loss of PSMA expression in a subset of EAC cases could be due to epigenetic silencing.

  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349274.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


61. Cowell JK, Head K, Kunapuli P, Vaughan M, Karasik E, Foster B: Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer. Exp Mol Pathol; 2010 Feb;88(1):77-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer.
  • To determine whether human prostate cancer cells (PC3, 22RV, Du145) are similarly affected by exposure to LGI1, we conducted scratch wound assays and demonstrated that the secreted LGI1 protein can reduce cell motility, an essential component of invasion and metastasis.
  • These studies have now been extended to an in vivo mouse model of prostate cancer.
  • Using a BAC transgenic mouse expressing a GFP reporter gene under the control of cis regulatory elements, we demonstrated that LGI1 is highly expressed in the normal prostate epithelium.
  • To determine whether loss of LGI1 expression is associated with development and progression of murine prostate cancer, we bred the GFP reporter BAC transgenic mice with TRAMP mice which undergo early hyperplasia and progressive stages of prostate cancer.
  • In the F1 animals, although the surrounding normal prostate epithelium expressed high levels of LGI1 in the double transgenic mice, the LGI1 gene had been inactivated even at the earliest stages of hyperplasia.
  • Taken together these results suggest that LGI1 may be an important molecule for the arrest of prostate cancer cell invasion and possibly as a biomarker for early detection of prostate hyperplasia.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):255-66 [11907806.001]
  • [Cites] Nat Med. 2002 Mar;8(3):219-20 [11875488.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1992-8 [12466304.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):3985-91 [12821932.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):561-4 [12942323.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23151-7 [15047712.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):295-301 [1320666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Genomics. 1995 Jul 20;28(2):328-32 [8530044.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1329-35 [9769364.001]
  • [Cites] Oncogene. 1998 Dec 3;17(22):2873-81 [9879993.001]
  • [Cites] Hum Mol Genet. 2005 Jun 15;14(12):1613-20 [15857855.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1792-5 [16990550.001]
  • [Cites] Hum Mol Genet. 2006 Dec 1;15(23):3436-45 [17067999.001]
  • [Cites] Mamm Genome. 2007 May;18(5):328-37 [17565425.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):938-50 [18030362.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):236-46 [18156212.001]
  • [Cites] Oral Oncol. 2008 Oct;44(10):941-8 [18234543.001]
  • [Cites] Int J Biol Sci. 2008;4(6):387-96 [18974846.001]
  • [Cites] J Mol Neurosci. 2009 Sep;39(1-2):137-43 [19387870.001]
  • [Cites] Hum Mol Genet. 2002 May 1;11(9):1119-28 [11978770.001]
  • (PMID = 19778537.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS046706-05; United States / NINDS NIH HHS / NS / R01 NS046706; United States / NINDS NIH HHS / NS / NS46706; United States / NINDS NIH HHS / NS / R01 NS046706-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LGI1 protein, human; 0 / Proteins
  • [Other-IDs] NLM/ NIHMS153974; NLM/ PMC2815187
  •  go-up   go-down


62. Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, Odunsi K, Lele S, Liu S: Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One; 2010;5(11):e15415
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.
  • BACKGROUND: Endometrial cancer is the most common gynecologic malignancy in developed countries and little is known about the underlying mechanism of stage and disease outcomes.
  • The goal of this study was to identify differentially expressed genes (DEG) between late vs. early stage endometrioid adenocarcinoma (EAC) and uterine serous carcinoma (USC), as well as between disease outcomes in each of the two histological subtypes.
  • Remarkably, there was no overlap between the stage-derived DEGs and the prognosis-derived DEGs for each of the two histological subtypes.
  • CONCLUSION: This data, although preliminary, suggests that there might be involvement of distinct groups of genes in tumor progression (late vs. early stage) in each of the EAC and USC.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1364-9 [20009891.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):114-28 [19344752.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5697-702 [14522886.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5988-95 [14676124.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):181-91 [15013523.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):292-300 [15099936.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1622-7 [1540970.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5100-3 [8221644.001]
  • [Cites] Cancer. 1994 May 1;73(9):2380-5 [7909491.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3371-6 [9042194.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] J Soc Gynecol Investig. 1998 Sep-Oct;5(5):277-80 [9773404.001]
  • [Cites] Oncogene. 1998 Nov 26;17(21):2719-32 [9840936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8846-53 [15604243.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Bioessays. 2005 Jun;27(6):602-13 [15892119.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4056-66 [15930340.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Trends Mol Med. 2005 Jul;11(7):336-40 [15961345.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4741-53 [15897902.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2553-61 [16510572.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1088-94 [16570270.001]
  • [Cites] BMC Cancer. 2006;6:144 [16737551.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):979-87 [17592263.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75 [17576678.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):58-85 [17692468.001]
  • [Cites] Prostate. 2007 Dec 1;67(16):1770-80 [17929269.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):457-66 [18199540.001]
  • [Cites] Acta Pharmacol Sin. 2008 Mar;29(3):285-95 [18298893.001]
  • [Cites] Mol Biol Cell. 2008 Apr;19(4):1772-82 [18272789.001]
  • [Cites] PLoS Genet. 2008 Apr;4(4):e1000052 [18404217.001]
  • [Cites] Curr Issues Mol Biol. 2008;10(1-2):61-6 [18525107.001]
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):1547-8 [18467348.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):768-73 [18682706.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):505-11 [18928665.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):2083-7 [18985039.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2808-15 [18803288.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):143-51 [18979216.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):134-40 [19258955.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1095-102 [19277044.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Physiol Pharmacol. 2009 May;60 Suppl 1:57-63 [19609014.001]
  • [Cites] Semin Reprod Med. 2000;18(1):81-9 [11299523.001]
  • (PMID = 21079744.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE23518
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2975707
  •  go-up   go-down


63. de Muga S, Hernández S, Agell L, Salido M, Juanpere N, Lorenzo M, Lorente JA, Serrano S, Lloreta J: Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod Pathol; 2010 May;23(5):703-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.
  • Prostate cancer is the second cause of cancer-related death in men of the Western world.
  • The potential prognostic role of the combined alterations in EGFR and PTEN in prostate cancer is not well established.
  • Prevalence of EGFR and PTEN somatic mutations, EGFR amplification and EGFR protein expression were investigated in a series of prostate adenocarcinomas, classified according to the current Gleason grading system.
  • Mutational analysis revealed eight EGFR and three PTEN mutations in 98 (8%) and 92 (3%) prostate adenocarcinomas, respectively.
  • In 35% of adenocarcinomas we found some type of EGFR-PTEN alteration, with a tendency to be associated with advanced-stage prostate adenocarcinomas (P=0.04).
  • The IVS18+19 polymorphism was also associated with more advanced prostate adenocarcinomas.
  • This is the first study reporting mutations of EGFR and PTEN in the same series of prostate adenocarcinomas.
  • Mutations in EGFR and PTEN genes are a minor event, although prostate cancer represents the third neoplasm in which the EGFR gene mutations are more prevalent.
  • Alterations in the EGFR-PTEN signaling pathway are present in a third of prostate adenocarcinomas, particularly affecting the more advanced cases.
  • [MeSH-major] Adenocarcinoma / genetics. PTEN Phosphohydrolase / genetics. Prostatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics


64. Lopez-Beltran A, Cheng L, Prieto R, Blanca A, Montironi R: Lymphoepithelioma-like carcinoma of the prostate. Hum Pathol; 2009 Jul;40(7):982-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the prostate.
  • In this report, we summarized the clinicopathologic features of 5 cases of lymphoepithelioma-like carcinoma of the prostate, a rare variant of prostate cancer characterized by a malignant epithelial component densely infiltrated by lymphoid cells.
  • In all 5 patients, there were obstructive symptoms and elevated prostate-specific antigen; one patient had also hematuria.
  • The initial diagnosis of lymphoepithelioma-like carcinoma of the prostate was made on transurethral resection in 3 cases and radical prostatectomy in 2 others.
  • In one case the diagnosis of lymphoepithelioma-like carcinoma admixed with conventional acinar adenocarcinoma was an unexpected finding at time of transurethral resection for benign prostatic hyperplasia.
  • Three patients had clinical stage T3 tumors and another had stage T4 disease; stage T1b was present in the remaining case.
  • All cases were associated with adenocarcinoma, either as the sole pattern in 5 cases or with an additional ductal component in 3 cases.
  • Immunohistochemical staining demonstrated that lymphoepithelioma-like carcinoma was positive for prostate-specific antigen, prostate acid phosphatase, alpha-methylacyl coenzyme A racemase, and epithelial membrane antigen; several cytokeratins (AE1/AE3, 7, 8, and 20 [rare cells]) were also immunoreactive.
  • DNA ploidy of the concurrent adenocarcinoma gave DNA aneuploid peaks except in one DNA diploid case.
  • In summary, lymphoepithelioma-like carcinoma of the prostate arise in aggressive prostate cancers at advanced clinical stage.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269013.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Alongi F, Aniko MD, Ferreri AJ, Rosso A, Cozzarini C, Fallanca F, Berardi G, Schipani S, Gianolli L, Guazzoni G, Di Muzio N: Consolidation radiotherapy for a rare case of extranodal mucosa-associated lymphoid tissue non-Hodgkin's lymphoma synchronous with prostate adenocarcinoma. Tumori; 2010 May-Jun;96(3):498-502
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation radiotherapy for a rare case of extranodal mucosa-associated lymphoid tissue non-Hodgkin's lymphoma synchronous with prostate adenocarcinoma.
  • Nongastric primary extranodal mucosa-associated lymphoid tissue (MALT) lymphomas are uncommon, with around 0.1% occurring in the prostate.
  • Even less frequent is the presence of MALT lymphoma synchronous with another type of neoplasm in the same organ, especially the prostate.
  • Only a single case of concurrent adenocarcinoma and MALT lymphoma of the prostate has been reported in the literature.
  • We report a rare case of primary extranodal marginal zone MALT lymphoma incidentally diagnosed during radical prostatectomy for an adenocarcinoma of the prostate in a 53-year-old patient.
  • This preliminary result confirms that rare cases of MALT lymphoma of the prostate should be discussed and treated under the collaborative supervision of hematologists and medical and radiation oncologists.
  • In fact, at an advanced stage of the disease, a chemotherapy regimen with additional consolidation radiotherapy could be an effective strategy, as in all other lymphomas.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Neoplasms, Multiple Primary / radiotherapy. Prostatic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845817.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Resnick MJ, Wein AJ: Transitional cell carcinoma of the fossa navicularis in a man with preexisting adenocarcinoma of the prostate. Urol Int; 2006;76(2):186-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the fossa navicularis in a man with preexisting adenocarcinoma of the prostate.
  • In this report we present a patient with a history of prostatic adenocarcinoma who was found to have a low-grade/low-stage transitional cell carcinoma of the fossa navicularis.
  • Very limited follow-up data exist on which to base management decisions, and this report lends support to the use of transurethral resection alone as a means to treat low-grade/low-stage lesions.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms. Urethral Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493225.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Fontenot JD, Lee AK, Newhauser WD: Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):616-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.
  • PURPOSE: To assess the risk of a secondary malignant neoplasm (SMN) from proton therapy relative to intensity-modulated radiation therapy (IMRT) using X-rays, taking into account contributions from both primary and secondary sources of radiation, for prostate cancer.
  • METHODS AND MATERIALS: A proton therapy plan and a 6-MV IMRT plan were constructed for 3 patients with early-stage adenocarcinoma of the prostate.
  • CONCLUSIONS: When considering exposure to primary and secondary radiation, proton therapy can reduce the risk of an SMN in prostate patients compared with contemporary IMRT.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Prostatic Neoplasms / radiotherapy. Protons / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):398-406 [10640974.001]
  • [Cites] Phys Med Biol. 2008 Apr 21;53(8):2131-47 [18369278.001]
  • [Cites] Phys Med Biol. 2008 Mar 21;53(6):1677-88 [18367796.001]
  • [Cites] Med Phys. 2008 Jan;35(1):128-44 [18293570.001]
  • [Cites] Radiother Oncol. 2008 Feb;86(2):165-70 [18192046.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744-51 [17904306.001]
  • [Cites] Phys Med Biol. 2008 Jan 7;53(1):187-201 [18182696.001]
  • [Cites] Med Phys. 2007 Sep;34(9):3449-56 [17926946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):444-53 [17513063.001]
  • [Cites] Technol Cancer Res Treat. 2007 Aug;6(4 Suppl):31-4 [17668949.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):892-7 [17459608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):620-9 [17236979.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):647-52 [17072522.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):991-8 [16878323.001]
  • [Cites] Health Phys. 2006 Jun;90(6):554-64 [16691103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Int J Radiat Biol. 2004 May;80(5):327-37 [15223765.001]
  • [Cites] Med Phys. 1977 Jul-Aug;4(4):297-301 [407436.001]
  • [Cites] Med Phys. 1995 Jan;22(1):63-82 [7715571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304 [9788407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):947-53 [10386654.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1510-5 [15817357.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):819-24 [15825064.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1204-16 [15990026.001]
  • [Cites] Med Phys. 2006 Feb;33(2):360-8 [16532941.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7 [16618572.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1624; author reply 1624-5 [19931743.001]
  • (PMID = 19427561.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131463; United States / NCI NIH HHS / CA / R01 CA131463-01A1
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  • [Other-IDs] NLM/ NIHMS180052; NLM/ PMC4120808
  •  go-up   go-down


68. Mai KT, Belanger EC, Al-Maghrabi HM, Robertson S, Wang D, Margnean C: Primary prostatic central zone adenocarcinoma. Pathol Res Pract; 2008;204(4):251-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prostatic central zone adenocarcinoma.
  • The central zone (CZ) of the prostate is embryologically, anatomically, and histologically distinct.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma (PAC) are encountered in the CZ, but have not been well studied.
  • The correlating positive biopsy cores were from the mid portion or from base of prostate and contained foci of HGPIN in 4/7 cases.
  • The CZ PAC is characteristically accompanied by more foci of HGPIN in the CZ than in non-CZ and is associated with high grade and high stage.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178014.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Wu TT, Wang JS, Jiaan BP, Yu CC, Tsai JY, Lin JT, Huang JK: Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. J Chin Med Assoc; 2007 Jan;70(1):11-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma.
  • BACKGROUND: Both p21(WAF1) and p27(KIP1) have been reported as prognostic markers predicting biochemical failure for prostate cancers.
  • We examined the expression and prognostic significance of p21(WAF1) and p27(KIP1) in organ-confined (pT2) prostate cancer patients.
  • METHODS: The medical records of 53 pT2 prostate adenocarcinomas were analyzed retrospectively.
  • Biochemical relapse was defined as 2 consecutive elevations in serum prostate specific antigen (PSA) level > 0.2 ng/mL with an interval of more than 3 months.
  • CONCLUSION: p21(WAF1) and p27(KIP1) expression have no role in predicting biochemical relapse for stage pT2 prostate cancers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Intracellular Signaling Peptides and Proteins / analysis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Apoptosis. Cyclin-Dependent Kinase Inhibitor p27. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Chin Med Assoc. 2007 Jan;70(1):3 [17276925.001]
  • (PMID = 17276927.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


70. Kannan V, Sathiyanarayanan VK, Sagde S, Anand V, Almel S, Kapadia A, Srinivas V: Three dimensional conformal radiation therapy in prostate adenocarcinoma: survival and rectal toxicity. J Cancer Res Ther; 2005 Jan-Mar;1(1):34-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three dimensional conformal radiation therapy in prostate adenocarcinoma: survival and rectal toxicity.
  • The 3D-CRT clinical treatment in our hospital was started in September 1998 and till December 2002, 51 patients with M(0) stage prostate carcinoma were treated.
  • Our experience suggests that a dose of 72 Gy by 3D-CRT can be safely delivered to the prostate and gastrointestinal tolerance during treatment and follow-up period was excellent.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Rectum / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998623.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


71. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H: Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):39-47
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
  • PURPOSE: To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive (125)I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting.
  • METHODS AND MATERIALS: Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of < or =10 ng/mL, and Gleason score of < or =6.
  • All patients underwent transrectal ultrasound-guided radioactive (125)I permanent seed implantation into the prostate.
  • The prescribed dose was 145 Gy to the prostate planning target volume.
  • At last follow-up, no patient had died of prostate cancer or related toxicities.
  • CONCLUSION: The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through the Radiation Therapy Oncology Group.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy. Ultrasonography, Interventional / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084551.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


72. Matousková M: [Prostate cancer]. Klin Onkol; 2008;21(5):280-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer].
  • [Transliterated title] Karcinom prostaty.
  • Malignant prostate tumors rank with its incidence among the most frequent tumors in man in Czech Republic.
  • Adenocarcinoma of the prostate due to its unusual behavior occupy especial position among solid tumors.
  • After the introduction of PSA in the diagnostic methods we can gradually see shift of the new cases of prostate cancer to the localised stage.
  • Movement to less localized stage diminishes the chance of recovery, but even the metastatic adenocarcinoma can be stabilised at least for some time.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202959.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 12
  •  go-up   go-down


73. Hammer A, Hager H, Steiniche T: Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer. APMIS; 2008 Jan;116(1):81-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer.
  • Extramammary Paget's disease (EMPD) is a rare intraepidermal adenocarcinoma that primarily affects the anogenital region.
  • Cases of EMPD reacting with PSA (prostate-specific antigen) have previously been associated with underlying prostate cancer.
  • However, a recent case of EMPD in our department has led us to question the value of PSA as an indicator of underlying prostate cancer.
  • Three of the five patients had been diagnosed with internal malignant disease-two with prostate cancer, stage 1.
  • Immunohistochemical investigations of the tumour specimens from the prostate revealed an immunoprofile which was very different from that of the primary skin lesion.
  • In our study, no cases of EMPD with PSA positivity seem to represent an extension of an underlying prostatic adenocarcinoma.
  • PSA positivity can be seen in cases of EMPD without associated adenocarcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / metabolism. Paget Disease, Extramammary / metabolism. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / metabolism. Skin Neoplasms / metabolism


74. Bălăşoiu M, Turculeanu A, Avrămescu C, Comănescu V, Simionescu C, Mogoantă L: Cytokines levels in prostate adenocarcinomas. Rom J Morphol Embryol; 2005;46(3):179-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines levels in prostate adenocarcinomas.
  • In this research, we determined the levels of IL-2, IL-6 and TNF-alpha at 60 patients with prostate adenocarcinomas situated in II, III and IV stages.
  • We observed that the IL-2 levels were normal in II stage, and the levels of IL-6 and TNF-alpha were lightly increased.
  • In III and IV stages of prostate cancer the levels of IL-2 were very low and the levels of IL-6 and TNF-alpha were very increased.
  • The decrease of IL-2 levels in advanced prostate cancer goes to the decrease of immune response in prostate cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Cytokines / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444302.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


75. Ahmed H, Cappello F, Rodolico V, Vasta GR: Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol; 2009 Aug 18;2(3):146-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.
  • Galectins, soluble intracellular and extracellular beta-galactoside-binding proteins, are known to be involved in the progression and metastasis of various cancers, including prostate adenocarcinoma, but the detailed mechanism of their biological roles remains elusive.
  • In the prostate cancer cell lines PC-3 and DU-145, galectin 3 (gal3) is present at normal levels, whereas in LNCaP, its expression is silenced.
  • On immunohistochemical analysis of normal and tumor prostate tissues, gal3 was found expressed both in nucleus and cytoplasm of benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, and stage I.
  • On methylation analysis, the gal3 promoter in stage II prostate adenocarcinoma (PCa) was found heavily methylated, whereas in stages III and IV, it was only lightly methylated.
  • However, in stage I PCa, both heavy and light methylations were observed in the gal3 promoter.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):567-78 [17786537.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2353-63 [10590378.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):143-58 [17635792.001]
  • [Cites] Cell Mol Life Sci. 2007 Jul;64(13):1679-700 [17497244.001]
  • [Cites] Front Biosci. 2007;12:3377-97 [17485307.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):241-6 [17481580.001]
  • [Cites] Urology. 2007 Apr;69(4):714-20 [17445657.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Sep;6(6):533-51 [17017872.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6569-75 [16170165.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):623-31 [10230352.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):519-26 [10225438.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 1;90(13):1000-8 [9665149.001]
  • [Cites] Arch Biochem Biophys. 1998 Jan 1;349(1):7-20 [9439577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7252-7 [8692978.001]
  • [Cites] Curr Opin Genet Dev. 1995 Jun;5(3):309-14 [7549424.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] J Urol. 1994 Jun;151(6):1571-4 [7514690.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):474-80 [8112883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5518-22 [15328191.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Jul;4(4):513-26 [15225099.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):101-7 [15096565.001]
  • [Cites] Glycobiology. 2004 Mar;14(3):219-32 [14693912.001]
  • [Cites] Glycoconj J. 2004;19(7-9):537-42 [14758077.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):241-57 [11915942.001]
  • [Cites] Clin Chim Acta. 2001 Nov;313(1-2):143-6 [11694252.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2727-30 [11555585.001]
  • [Cites] Histol Histopathol. 2001 Jul;16(3):861-8 [11510978.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4820-6 [11406558.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • [Cites] Clin Chem. 2000 Aug;46(8 Pt 1):1078-84 [10926886.001]
  • [Cites] Prostate. 2000 Jul 1;44(2):118-23 [10881021.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] Clin Chem. 2008 May;54(5):874-82 [18339699.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Jan;8(1):22-36 [18220503.001]
  • [Cites] Urol Res. 1999 Oct;27(5):362-7 [10550525.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):605-10 [17726578.001]
  • (PMID = 19701499.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM070589
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730137
  •  go-up   go-down


76. Samaratunga H, Duffy D, Yaxley J, Delahunt B: Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol; 2010 Feb;41(2):281-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
  • Ductal adenocarcinoma of the prostate is an aggressive malignancy, often presenting at an advanced stage.
  • In mixed ductal and acinar adenocarcinomas, the relationship between the proportion of the ductal component of the tumor and the pathologic stage and whether or not aggressive behavior is simply a function of grade remains undetermined.
  • From 268 consecutive radical prostatectomies undertaken as a curative procedure for clinical localized prostate cancer, we identified 34 cases (12.7%) with ductal adenocarcinoma of the prostate comprising 5% to 100% of the total tumor volume.
  • For cases with a ductal adenocarcinoma of the prostate component, the mean age at diagnosis of 60 years (range 49-69 years), mean serum prostate-specific antigen of 8.4 ng/mL (range, 0.8-21 ng/mL) and positive surgical margin rate of 17.6% did not differ significantly from that of the pure adenocarcinoma group.
  • All 34 patients with ductal adenocarcinoma of the prostate had peripheral zone involvement while 16 (46%) also had transition zone involvement.
  • Twenty-five (73%) cases with ductal adenocarcinoma of the prostate had extraprostatic extension (pT3), which compared to 32.9% with acinar adenocarcinoma.
  • The presence of ductal adenocarcinoma of the prostate (P < .0001), high tumor volume (P = .001) and Gleason score >7 (P = .04) significantly predicted pT3 staging category, and the presence of ductal adenocarcinoma of the prostate remained a significant predictor for pT3, after adjusting for tumor volume and Gleason score >7.
  • The proportion of ductal adenocarcinoma of the prostate did not significantly modify the strength of the observed association with pathological stage.
  • In view of the significant association with extraprostatic extension we would recommend that in both core biopsies and radical prostatectomy specimens any proportion of ductal adenocarcinoma of the prostate should be reported.
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Prostate-Specific Antigen / blood. Prostatectomy. Regression (Psychology)

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Hum Pathol. 2011 Apr;42(4):605-6; author reply 606-7 [21237485.001]
  • (PMID = 20004936.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


77. Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F: Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int; 2008;80(1):68-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
  • BACKGROUND/AIM: To compare serum chromogranin A (CgA) and insulin-like growth factor 1 (IGF-1) with the classical prostate-specific antigen (PSA) marker in clinically localized prostate adenocarcinomas.
  • MATERIALS AND METHODS: This is a prospective single-center study that included 64 consecutive men with newly diagnosed clinically localized prostate adenocarcinoma and 20 consecutive men with histologically confirmed benign prostatic hyperplasia (BPH).
  • Analysis of variance was performed to evaluate their variations according to disease and the pathological characteristics of prostate adenocarcinoma.
  • RESULTS: Only serum PSA levels (p < 0.0001) and not IGF-1 (p = 0.5475) or CgA (p = 0.5043) were significantly higher in the prostate cancer (PCa) group as compared to the BPH group.
  • A significant variance between BPH and PCa divided on the basis of pT stage was found for PSA levels (p < 0.0001) but not for CgA (p = 0.0869) and IGF-1 (p = 0.6883) levels.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Chromogranin A / blood. Insulin-Like Growth Factor I / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Hyperplasia / blood. Prostatic Neoplasms / blood


78. Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI: Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol; 2008 Jun;179(6):2203-6; discussion 2206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.
  • PURPOSE: We examined contralateral prostate cancer potentially left behind by focal therapy.
  • Clinical stage was T1c in 85 and T2a in 15 cases with the palpable lesion on the positive biopsy side.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Technol Cancer Res Treat. 2004 Aug;3(4):365-70 [15270587.001]
  • [Cites] Urology. 2004 Oct;64(4):733-7 [15491711.001]
  • [Cites] Cancer. 1972 Jul;30(1):5-13 [5064808.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2313-8 [1382830.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):368-74 [7506797.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):906-10 [17587207.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):174-8 [9042283.001]
  • [Cites] Tech Urol. 1999 Sep;5(3):139-42 [10527256.001]
  • [Cites] J Endourol. 2006 Sep;20(9):688-92 [16999628.001]
  • [Cites] BJU Int. 2006 Nov;98(5):986-8 [17034600.001]
  • [Cites] Urology. 2007 Jun;69(6):1117-20 [17572198.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):987-92 [7853589.001]
  • [CommentIn] J Urol. 2008 Jun;179(6):2091 [18423729.001]
  • (PMID = 18423736.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / CA 58236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS374261; NLM/ PMC3353270
  •  go-up   go-down


79. DeHaan AM, Wolters NM, Keller ET, Ignatoski KM: EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate; 2009 Apr 1;69(5):528-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.
  • BACKGROUND: Bone metastasis occurs frequently in advanced prostate cancer (PCa) patients; however, it is not known why this happens.
  • The epidermal growth factor receptor (EGFR) ligand EGF is available to early stage PCa; whereas, TGF-alpha is available when PCa metastasizes.
  • METHODS: We used LNCaP cells as a model of early stage, non-metastatic PCa and the isogenic C4-2B cells as a model of late stage, metastatic PCa.
  • Therefore, AKT appeared to be the TGF-alpha-responsive factor for survival of the late stage PCa cells.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Bone. 1999 Nov;25(5):517-23 [10574571.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1038-45 [10741732.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 11):2-8 [11544569.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):13-9 [12447985.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1200-10 [12631626.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):1-21 [12653668.001]
  • [Cites] Mol Cancer Res. 2003 May;1(7):551-60 [12754302.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Annu Rev Biochem. 1987;56:881-914 [3039909.001]
  • [Cites] Eur J Cancer. 1992;28(1):263-7 [1348953.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Dec;77(6):1472-8 [8263129.001]
  • [Cites] Mol Cell Biochem. 1993 Sep 22;126(2):151-8 [7508078.001]
  • [Cites] Mod Pathol. 1993 Nov;6(6):733-7 [7508115.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2577-81 [8168083.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):406-12 [8169003.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):167-75 [7824269.001]
  • [Cites] Proc Soc Exp Biol Med. 1995 Nov;210(2):162-70 [7568287.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1546-56 [9362421.001]
  • [Cites] Clin Cancer Res. 1995 May;1(5):545-50 [9816014.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):657-69 [10360641.001]
  • [Cites] Endocrinology. 1999 Aug;140(8):3615-22 [10433219.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18 [15615499.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):21-8 [15630412.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):630-40 [15700310.001]
  • [Cites] Thromb Haemost. 2005 May;93(5):964-75 [15886816.001]
  • [Cites] Prostate. 2005 Jun 15;64(1):1-8 [15651060.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(10):1467-73 [15919200.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7554-60 [16140917.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):661-72 [16447163.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):197-210 [16601288.001]
  • [Cites] Cancer. 2006 May 1;106(9):1917-24 [16568471.001]
  • [Cites] Prostate. 2006 Sep 15;66(13):1437-44 [16741920.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):551-8 [17160558.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):269-76 [17211467.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):400-4 [18379359.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):820-9 [18324676.001]
  • [Cites] Ann Rheum Dis. 2000 Jan;59(1):26-31 [10627423.001]
  • (PMID = 19143022.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098513-05; United States / NCI NIH HHS / CA / R01 CA098513; United States / NCI NIH HHS / CA / P01 CA093900; United States / NCI NIH HHS / CA / R01 CA098513-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / RANK Ligand; 0 / TNFSF11 protein, human; 0 / Transforming Growth Factor alpha; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  • [Other-IDs] NLM/ NIHMS129704; NLM/ PMC2766509
  •  go-up   go-down


80. Jubinsky PT, Short MK, Mutema G, Morris RE, Ciraolo GM, Li M: Magmas expression in neoplastic human prostate. J Mol Histol; 2005 Feb;36(1-2):69-75
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magmas expression in neoplastic human prostate.
  • Because GM-CSF receptor levels are elevated in prostate cancer, Magmas expression was examined in normal and neoplastic tissue.
  • Magmas protein levels were barely detectable in non-neoplastic prostate glands.
  • Approximately one half of the adenocarcinoma samples examined had weak Magmas expression, while the remainder had intermediate to high levels.
  • Interestingly, in some patients, the normal prostate tissue had more Magmas message than the malignant portion.
  • The results indicated that Magmas expression in prostate cancer is heterogeneous and independent of clinical stage and Gleason score.
  • Further studies are needed to determine if Magmas expression has prognostic significance in prostate cancer.
  • [MeSH-minor] Humans. Male. Mitochondria / metabolism. Mitochondria / ultrastructure. Neoplasm Staging. Prognosis. Prostate / chemistry. Prostate / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704001.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / magmas protein, human
  •  go-up   go-down


81. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst; 2005 Jan 19;97(2):142-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.
  • BACKGROUND: The incidence of esophageal adenocarcinoma is rising dramatically.
  • METHODS: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results database to extract information on incidence, stage distribution, and disease-specific mortality for esophageal adenocarcinoma as well as information on related cancers.
  • RESULTS: From 1975 to 2001, the incidence of esophageal adenocarcinoma rose approximately sixfold in the United States (from 4 to 23 cases per million), a relative increase greater than that for melanoma, breast, or prostate cancer.
  • The only location with increased incidence is the lower third of the esophagus-the site where adenocarcinoma typically arises.
  • Because there has been little change in the proportion of patients found with in situ or localized disease at diagnosis since 1975 (from 25% to 31%) and because esophageal adenocarcinoma mortality has increased more than sevenfold (from 2 to 15 deaths per million), overdiagnosis can be excluded as an explanation for the rise in incidence.
  • CONCLUSION: The rising incidence of esophageal adenocarcinoma represents a real increase in disease burden.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / epidemiology. Esophageal Neoplasms / classification. Esophageal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Nature Publishing Group. commentaries/discussion - Highlights from Nature Reviews Cancer .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jul 6;97(13):1013-4; author reply 1014 [15998956.001]
  • (PMID = 15657344.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


82. Yamashita R, Matsuzaki M, Matsui T, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K: [Clinical characteristics of prostatic adenocarcinoma with ductal features]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of prostatic adenocarcinoma with ductal features].
  • PURPOSE: To determine the incidence and prognosis of prostatic ductal adenocarcinoma.
  • We differentiated prostatic cases of ductal adenocarcinoma that were larger than 5 mm in diameter from cases of acinar adenocarcinomas.
  • We then examined these two groups for the pathological stages of the neoplasms and the incidence of postoperative prostate-specific antigen (PSA) failure.
  • RESULTS: We found eight cases (12%) of prostatic ductal adenocarcinoma among the 64 cases treated with radical prostatectomies.
  • In addition, one case was identified as pure ductal adenocarcinoma.
  • During the follow-up period, four of the eight cases of ductal adenocarcinoma (50%) and twelve of the 56 cases of acinar adenocarcinoma (21%) showed postoperative PSA failure.
  • CONCLUSIONS: We identified eight cases of ducal adenocarcinoma (12% of the examined cases), which suggests this disease is not as rare as previously reported.
  • Compared to the cases of acinar adenocarcinoma, the cases of ductal adenocarcinoma were at a more advanced pathological stage and resulted in a higher rate of postoperative PSA failure.
  • Therefore, we believe that patients that show even a limited degree of ductal adenocarcinoma should receive aggressive therapy.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / therapy. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404881.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


83. Nikoleishvili D, Pertia A, Tsintsadze O, Gogokhia N, Chkhotua A: Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades. Georgian Med News; 2007 Feb;(143):34-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
  • The goal of the study was to analyze the expression of p27(Kip 1) cyclin-dependent kinase inhibitor protein (CDKI) in different cells of benign, malignant and hormonally treated prostate cancer tissue and assess their possible association with different clinical parameters.
  • Expression of p27(Kip 1) CDKI was evaluated and compared in: 32 BPH, 20 prostate cancer (PCa) and 6 hormonally treated prostate cancer (HTPCa) tissues.
  • In the PCa group, the intensity of the protein expression was negatively associated with the tumor stage, Gleason scores 1, 2, and the Gleason sum (p=0.0453, 0.0202, 0.0074 and 0.0098, respectively).
  • The intensity of the expression in these cells is associated with tumor stage and grades.
  • The hormonotherapy is causing up-regulation of p27(Kip 1) expression in prostate adenocarcinoma cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17404436.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


84. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Pejcic T, Hadzi-Djokic J, Markovic B, Maksimovic H, Acimovic M, Miljkovic S: Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. Acta Chir Iugosl; 2007;54(4):109-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions.
  • OBJECTIVE: To present the case of T2 prostate cancer (PCa) mimicking disseminated PCa that was successfully treated with radical retropubic prostatectomy (RRP).
  • PATIENT AND THE METHOD: The patient had prostate specific antigen (PSA) level higher than 30 ng/ml and multiple atypical lesions on bone scan.
  • [MeSH-major] Adenocarcinoma / blood. Bone and Bones / radionuclide imaging. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology


86. Mitsumori M, Sasaki Y, Mizowaki T, Takayama K, Nagata Y, Hiraoka M, Negoro Y, Sasai K, Kinoshita H, Kamoto T, Ogawa O: Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. Int J Clin Oncol; 2006 Oct;11(5):396-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
  • BACKGROUND: We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer.
  • Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
  • METHODS: Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058138.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


87. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB: Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res; 2007 Sep 1;67(17):7991-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
  • Recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS family transcription factors ERG, ETV1, and ETV4 have been identified in the majority of prostate adenocarcinomas (PCA).
  • Pathologic stage, size, or Gleason grade of the multifocal PCA did not correlate with overall TMPRSS2 rearrangement.
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Heterogeneity. Neoplasms, Multiple Primary / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804708.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA69568; United States / NCI NIH HHS / PC / PC040517; United States / NCI NIH HHS / CA / U01 CA111275-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  •  go-up   go-down


88. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol; 2010;4(1):32-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of CD133 expression in stage I lung adenocarcinomas.
  • This study evaluated the potential prognostic value of CD133 expression in stage I lung adenocarcinomas (ADC).
  • In conclusion, the level of CD133 expression is an independent prognostic marker and its combination with proliferating activity and/or vessel invasion could have excellent prognostic value to predict postoperative recurrence in patients with stage I lung ADC.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / metabolism. Glycoproteins / metabolism. Lung Neoplasms / metabolism. Peptides / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2009 Nov 20;122(22):2763-9 [19951611.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):355-62 [19162366.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):709-17 [19724847.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6 [19805294.001]
  • [Cites] Lung Cancer. 2009 Dec;66(3):275-81 [19716622.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Cancer Res. 2010 Jan 15;70(2):719-29 [20068153.001]
  • [Cites] BMC Cancer. 2010;10:218 [20487522.001]
  • [Cites] Oncol Rep. 2010 Aug;24(2):537-46 [20596644.001]
  • [Cites] J Gastroenterol. 2010 Aug;45(8):896-902 [20379837.001]
  • [Cites] Oncol Rep. 2010 Nov;24(5):1201-12 [20878111.001]
  • [Cites] Prostate. 2011 Jan 1;71(1):18-25 [20583131.001]
  • [Cites] Med Oncol. 2011 Dec;28(4):1458-62 [20717756.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1532-41 [17702091.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):46-52 [18166840.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):45-51 [18196970.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] PLoS One. 2008;3(7):e2637 [18612434.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] J Histochem Cytochem. 2008 Nov;56(11):977-93 [18645205.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8205-12 [19088037.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):71-8 [18790545.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):370-4 [9708203.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2018-25 [15545971.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 [17097610.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Lung Cancer. 2007 Jun;56(3):341-8 [17350137.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 May;27(5):696-9 [17545092.001]
  • (PMID = 21228926.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC3016102
  • [Keywords] NOTNLM ; CD133 / Lungadenocarcinoma / cancer stem cell / prognosis / stage I
  •  go-up   go-down


89. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys; 2007 Nov 15;69(4):1084-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
  • PURPOSE: To assess in a prospective trial the feasibility and late toxicity of hypofractionated radiotherapy (RT) for prostate cancer.
  • METHODS AND MATERIALS: Eligible patients had clinical stage T1c-2cNXM0 disease.
  • The cohort had a median prostate-specific antigen value of 7.06 ng/mL.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Biopsy. Dose Fractionation. Feasibility Studies. Humans. Male. Prospective Studies. Prostate / pathology. Prostate-Specific Antigen / blood. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606331.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


90. Raabe NK, Lilleby W, Tafjord G, Aström L: [High dose rate brachytherapy in prostate cancer in Norway]. Tidsskr Nor Laegeforen; 2008 May 29;128(11):1275-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose rate brachytherapy in prostate cancer in Norway].
  • BACKGROUND: A correlation exists between applied dose to the prostate and local tumour control.
  • External radiotherapy of the prostate implies administering curative doses near the upper limit of normal tissue tolerance.
  • Brachytherapy with a high dose rate permits an escalation of dose within the prostate without increasing the risk of side effects to the surrounding rectum and bladder.
  • This article presents a study of the first 100 patients in Norway with localized/locally advanced prostate cancer treated with high dose-rate brachytherapy combined with external radiotherapy.
  • MATERIAL AND METHODS: Patients belonging to an intermediate or high risk group and patients in whom radiotherapy was expected to give rise to increased toxicity (irrespective of the clinical stage) were included.
  • High dose rate brachytherapy is indicated in patients with prostate cancer of an intermediate or high risk or if a radiation dose with a full external beam proposes a hazard to the patient.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511969.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


91. Tanaka H, Masuda H, Komai Y, Yokoyama M, Iwai A, Numao N, Sakai Y, Saito K, Fujii Y, Kobayashi T, Kawakami S, Kihara K: [Primary adenocarcinoma of the female urethra treated by multimodal therapy]. Hinyokika Kiyo; 2009 Jan;55(1):43-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the female urethra treated by multimodal therapy].
  • Serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9 were elevated, but squamous cell carcinoma antigen and prostate specific antigen were within normal limits.
  • Pathological examinations of the transurethral and transvaginal needle biopsy specimen suggested mucinous adenocarcinoma.
  • Histopathological examination of the surgical specimen showed mutinous adenocarcinoma invading to the vesical triangle and the anterior vaginal wall.
  • The final diagnosis was urethral adenocarcinoma, pT4N0, Stage IV.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Urethral Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227213.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Venkitaraman R, Norman A, Woode-Amissah R, Dearnaley D, Horwich A, Huddart R, Parker C: Prostate-specific antigen velocity in untreated, localized prostate cancer. BJU Int; 2008 Jan;101(2):161-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen velocity in untreated, localized prostate cancer.
  • OBJECTIVE: To report the results of a prospective study of active surveillance of untreated prostate cancer, with a focus on baseline predictors of prostate-specific antigen (PSA) velocity, as PSA velocity before treatment is an important predictor of prostate cancer mortality, and patients on active surveillance are monitored for several years to estimate the PSA velocity and thus select patients for radical treatment.
  • PATIENTS AND METHODS: A prospective study of active surveillance for localized prostate cancer opened at the Royal Marsden Hospital in 2002.
  • Eligible patients had clinical stage T1/T2a, N0/Nx, M0/Mx adenocarcinoma of the prostate with a serum PSA level of < 15 ng/mL, a Gleason score of < or = 7 with primary grade < or = 3, and less than half the biopsy cores positive.
  • On multivariate analysis, PSA density (i.e. serum PSA level/prostate volume) was the only significant determinant of PSA velocity (P < 0.001).
  • CONCLUSIONS: PSA density, which is readily available at the time of diagnosis, is an independent determinant of PSA velocity in untreated, localized prostate cancer.
  • [MeSH-major] Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology


93. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM: Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1487-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of biochemical failure definitions for permanent prostate brachytherapy.
  • PURPOSE: To assess prostate-specific antigen (PSA) failure definitions for patients with Stage T1-T2 prostate cancer treated by permanent prostate brachytherapy.
  • METHODS AND MATERIALS: A total of 2,693 patients treated with radioisotopic implant as solitary treatment for T1-T2 prostatic adenocarcinoma were studied.
  • CONCLUSIONS: For patients treated by permanent radioisotopic implant for prostate cancer, the definition nadir + 2 ng/mL provides the best surrogate for failure throughout the entire follow-up period, similar to patients treated by external beam radiotherapy.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750326.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


94. Hughes L, Waterman FM, Dicker AP: Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base. Brachytherapy; 2005;4(2):163-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of suboptimal prostate seed implantation: Reimplantation of underdosed region of prostate base.
  • PURPOSE: To demonstrate how a suboptimal (125)I prostate implant can be salvaged by reimplantation.
  • METHODS AND MATERIALS: A (125)I implant was preplanned to deliver 150 Gy to the prostate of a patient with early stage prostate cancer.
  • CONCLUSION: It is feasible to salvage a suboptimal prostate seed implant by reimplanting the underdosed regions under fluoroscopy guidance based on a plan generated from the postimplant CT scan.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / instrumentation. Prostatic Neoplasms / radiotherapy. Prostheses and Implants. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893271.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


95. Thompson IM, Ankerst DP: Prostate-specific antigen in the early detection of prostate cancer. CMAJ; 2007 Jun 19;176(13):1853-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen in the early detection of prostate cancer.
  • Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer.
  • Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and -volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer.
  • The recently developed risk calculator from the Prostate Cancer Prevention Trial, which integrates family history of prostate cancer, digital rectal examination findings, PSA test result, age, ethnicity, and history of a prior prostate biopsy with a negative result, allows clinicians to assess a patient's individual risk of cancer.
  • This risk should be examined in the context of a patient's life expectancy and comorbidity as well as his concern about the possibility of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2000 Mar;11(2):167-70 [11021614.001]
  • [Cites] BMJ. 2004 Jul 17;329(7458):168-9 [15258077.001]
  • [Cites] Urology. 2004 Aug;64(2):311-5; discussion 315-6 [15302485.001]
  • [Cites] Br Med Bull. 1971 Jan;27(1):3-8 [5100948.001]
  • [Cites] Biometrics. 1983 Mar;39(1):207-15 [6871349.001]
  • [Cites] J Urol. 1984 Oct;132(4):690-2 [6471214.001]
  • [Cites] J Urol. 1987 Apr;137(4):686-9 [2435927.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):909-16 [2442609.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] N Engl J Med. 1991 Apr 25;324(17):1156-61 [1707140.001]
  • [Cites] Urol Clin North Am. 1991 Aug;18(3):459-65 [1877107.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):846-51; discussion 851-2 [1371560.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] JAMA. 1993 Aug 25;270(8):948-54 [7688438.001]
  • [Cites] Clin Invest Med. 1993 Dec;16(6):448-57 [7516833.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1682-4 [7933226.001]
  • [Cites] Urology. 1996 Aug;48(2):234-9 [8753735.001]
  • [Cites] Tex Med. 1996 Dec;92(12):59-67 [8979762.001]
  • [Cites] JAMA. 1997 May 14;277(18):1452-5 [9145717.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1845-51 [9351558.001]
  • [Cites] Can J Public Health. 1997 Sep-Oct;88(5):327-32 [9401168.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1817-23 [9839522.001]
  • [Cites] Can Oncol Nurs J. 1998 Nov;8(4):262-4 [9866477.001]
  • [Cites] CMAJ. 1999 Jan 12;160(1):70-5 [9934349.001]
  • [Cites] Urology. 1999 Mar;53(3):581-9 [10096388.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):433-8 [15770007.001]
  • [Cites] N Engl J Med. 2005 May 12;352(19):1977-84 [15888698.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):66-70 [15998892.001]
  • [Cites] J Urol. 2005 Aug;174(2):553-6; discussion 556 [16006890.001]
  • [Cites] Prostate. 2006 May 1;66(6):625-31 [16388507.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):529-34 [16622122.001]
  • [Cites] Can J Public Health. 2006 May-Jun;97(3):171-6 [16827400.001]
  • [Cites] Urology. 2006 Dec;68(6):1152-5 [17169636.001]
  • [Cites] J Gen Intern Med. 2000 Oct;15(10):749-51 [11089719.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2695-8 [11980670.001]
  • [Cites] Semin Urol Oncol. 2002 May;20(2):82-8 [12012293.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] J Urol. 2002 Sep;168(3):914-21 [12187190.001]
  • [Cites] BMJ. 2002 Oct 5;325(7367):740 [12364300.001]
  • [Cites] Chronic Dis Can. 2002 Summer;23(3):111-9 [12443567.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] Can J Urol. 2003 Dec;10(6):2040-50 [14704108.001]
  • [Cites] BJU Int. 2004 Mar;93(4):499-502 [15008717.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] J Urol. 2004 Jul;172(1):94-7 [15201745.001]
  • (PMID = 17576986.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / UO1 CA 86402
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 48
  • [Other-IDs] NLM/ PMC1891131
  •  go-up   go-down


96. Salirrosas SV, Armborgo J, Mostacero M: Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer. Acta Chir Iugosl; 2005;52(4):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer.
  • PURPOSE: This report provides information about clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer in the Regional Hospital from Trujillo, Peru.
  • MATERIALS AND METHODS: Retrospective, descriptive observation study of all the clinical histories from patients with histopathology diagnosis of prostate cancer during the period of January 2000 - December 2004.
  • The sample was constituted by 60 patients with clinics histories, study by image based on the prostate ecography and the prostate specific antigen results.
  • In the levels of prostate antigen the PSA found values between 10-50 ng/ml, in 48.78% of the patients.
  • In the ecography prostate study there where evidence of hypoecogenic images in 56%, hyperecogenics images 12%, heterogenics images 20% and 12% homogenics images.
  • In the TNM classification the higher percentage is located in T stage with an 81.67%, and in smaller proportions in the N1 and M1 stages with 8.33% and 10.0% respectively.
  • CONCLUSIONS: All the patients with prostate cancer showed a clinical symptoms about, obstructive and irritative and in other organs a less percentage of symptoms that shows metastases; in more than a half of the patients, the digital rectal examination showed nodules and irregularities in its surface; in the prostate ecography it is report a higher percentage of hypoecogenics images suggestive of neoplasia.
  • The levels of specific prostate antigen in more than 70% of the patients where over of 10 ng/ml; in the totally of the patients the histological type most frequent is the Adenocarcinoma, with a high grade of percentage of patients who had been bad prognosticated according to the Gleason score.
  • According the NTM, more of the two thirds parts of patients with prostate cancer are in T stage, with a high percentage extending on the prostatic capsule.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis


97. Kanno H, Umemoto S, Izumi K, Hasumi H, Osada Y, Ohta J, Mikata K, Tuchiya F: [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens]. Nihon Hinyokika Gakkai Zasshi; 2006 May;97(4):649-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
  • PURPOSE: We investigated prostate cancer (ca.) development after transurethral resection of the prostate (TURP).
  • Of them, 23 pts. (5.3%) had incidental carcinoma (Stage A), which developed into clinically significant ca. after 1 to 5 years in 5 (22% of Stage A, 1.2% of TURP).
  • In 13 (3.2%) of 407 Non-Stage A pts. (who had no ca. initially), prostate ca. developed after 1 to 7 yrs.
  • A total of 21 pts. (including 3 Stage A pts. diagnosed before 1994) underwent radical prostatectomy.
  • Stage A pts. received regular needle biopsy of prostate (Pbx).
  • Non-Stage A pts. were followed by yearly PSA measurement and digital rectal examination (DRE).
  • RESULTS: Clinically significant ca. developed in 8 Stage A pts. (all A2) after 1 to 14 yrs.
  • Long term (5 or 10 years) MAB therapy changed moderately-differentiated adenocarcinoma (AC) to poorly-differentiated AC in 2 pts. during follow-up.
  • Thirteen Non-Stage A pts. showed aggressive ca. (6 moderately-differentiated AC, 6 poorly-differentiated AC, and 1 ductal carcinoma which showed metastasis later), most of which invaded widely in peripheral zone (PZ).
  • Interval between TURP and diagnosis was short in pts. who had cancer of high Gleason Score (GS) or large prostate.
  • CONCLUSIONS: As significant cancer developed in 22% of Stage A pts. (1.2% of TURP) in long term follow-up, regular Pbx (to get TZ tissue) is mandatory regardless of PSA value or DRE.
  • Aggressive cancer developed in 3.2% of Non-Stage A pts. (3.0% of TURP). Pts. with high PSA or abnormal DRE after TURP must receive needle biopsy actively.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Transurethral Resection of Prostate
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prostate-Specific Antigen / blood. Prostatectomy. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768146.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


98. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther; 2009 Mar;16(3):206-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profile analysis of human prostate cancers.
  • We examined the microRNA (miRNA) expression profile of 40 prostatectomy specimens from stage T2a/b, early relapse and non-relapse cancer patients, to better understand the relationship between miRNA dysregulation and prostate oncogenesis.
  • Patient subset analysis showed that those with post-surgery elevation of prostate-specific antigen (chemical relapse) displayed a distinct expression profile of 16 miRNAs, as compared with patients with non-relapse disease.
  • These findings indicate that an altered miRNA expression signature accompanied the prostate oncogenic process.
  • Growth inhibition through the reconstitution of miRNAs is potentially applicable for experimental therapy of prostate cancer, pending molecular validation of targeted genes.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling. MicroRNAs / analysis. Prostatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949015.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN221 microRNA, human; 0 / MIRN222 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


99. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol; 2009 Sep 1;27(25):4047-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
  • PURPOSE: Prostatic acid phosphatase (PAP) is a prostate tumor antigen.
  • We report here the results of a phase I/IIa trial conducted with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer.
  • Overall, the prostate-specific antigen (PSA) doubling time was observed to increase from a median 6.5 months pretreatment to 8.5 months on-treatment (P = .033), and 9.3 months in the 1-year post-treatment period (P = .054).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] Immunol Invest. 2000 May;29(2):149-62 [10854184.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Prostate. 2001 May 15;47(3):222-9 [11351352.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):137-43 [11796010.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):79-93 [12957398.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5):659-66 [14571413.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):688-94 [15280930.001]
  • [Cites] Anat Rec. 1985 Oct;213(2):131-9 [3907418.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1049-58 [9230887.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3113-7 [9317107.001]
  • [Cites] JAMA. 1999 May 5;281(17):1591-7 [10235151.001]
  • [Cites] JAMA. 2005 Jul 27;294(4):433-9 [16046649.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):456-62 [15927415.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8669-73 [16361552.001]
  • [Cites] Vaccine. 2006 Jan 16;24(3):293-303 [16115700.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3089-94 [16809734.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):885-95 [17102977.001]
  • [Cites] Curr Opin Urol. 2007 May;17(3):175-81 [17414515.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1765-71 [17470867.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Jun;5(6):465-74, 477-9 [17679921.001]
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):e58; author reply e59 [20008614.001]
  • [CommentIn] J Clin Oncol. 2009 Sep 1;27(25):4035-7 [19635998.001]
  • (PMID = 19636017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR016489; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; United States / NCRR NIH HHS / RR / K23 RR16489
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Recombinant Proteins; 0 / Vaccines, DNA; 123774-72-1 / sargramostim; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2734418
  •  go-up   go-down


100. Appetecchia M, Meçule A, Pasimeni G, Iannucci CV, De Carli P, Baldelli R, Barnabei A, Cigliana G, Sperduti I, Gallucci M: Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. J Exp Clin Cancer Res; 2010;29:166
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
  • BACKGROUND: ChromograninA in prostate carcinoma (PC) indicate NE differentiation.
  • PSA was significantly associated with pT stage (pT2 with PSA abnormal 23.6% vs pT3 48.5%, p < 0.0001) and with a Gleason score (PSA abnormal 60% in the Gleason score was >7 vs 29.5% in the Gleason score = 7 vs 27.3% in the Gleason score <7, p < 0.0001).
  • Serum ChromograninA levels had no significant association with PSA (p = 0.44) and pT stage (p = 0.89).
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Chromogranin A / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2000 Mar 1;42(4):274-9 [10679756.001]
  • [Cites] Prostate. 2000 Mar 1;42(4):295-303 [10679759.001]
  • [Cites] J Urol. 2000 Apr;163(4):1161-4; discussion 1164-5 [10737487.001]
  • [Cites] Urology. 2000 Dec 20;56(6):1011-5 [11113749.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):7-15 [11391682.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S145-52 [11762343.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):512-5 [11792908.001]
  • [Cites] BJU Int. 2001 Nov;88(7):790-6 [11890255.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] Eur Urol. 2003 Aug;44(2):215-21 [12875941.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):421-8 [14968443.001]
  • [Cites] Dig Liver Dis. 2004 Feb;36 Suppl 1:S60-7 [15077913.001]
  • [Cites] Eur Urol. 2004 May;45(5):586-92; discussion 592 [15082200.001]
  • [Cites] NCI Monogr. 1988;(7):15-8 [3173500.001]
  • [Cites] J Urol. 1991 Aug;146(2):358-61 [1856931.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3952-65 [7685237.001]
  • [Cites] J Urol. 1996 Apr;155(4):1340-3 [8632569.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1756-64 [8656243.001]
  • [Cites] J Urol. 1997 Feb;157(2):565-8 [8996358.001]
  • [Cites] Prostate. 1997 Jan 1;30(1):1-6 [9018329.001]
  • [Cites] Prostate. 1998 Feb 1;34(2):113-20 [9465942.001]
  • [Cites] Prostate Suppl. 1998;8:18-22 [9690659.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):109-17 [15788643.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Jul-Aug;43(1):117-26 [16280180.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):229-34 [17177161.001]
  • [Cites] Prostate. 2007 May 1;67(6):645-52 [17342745.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1373 [17985422.001]
  • (PMID = 21162758.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC3018395
  •  go-up   go-down






Advertisement